Breast Cancer

Overview

Literature Analysis

Mouse over the terms for more detail; many indicate links which you can click for dedicated pages about the topic.

Tag cloud generated 08 August, 2015 using data from PubMed, MeSH and CancerIndex

Mutated Genes and Abnormal Protein Expression (1112)

How to use this data tableClicking on the Gene or Topic will take you to a separate more detailed page. Sort this list by clicking on a column heading e.g. 'Gene' or 'Topic'.

GeneLocationAliasesNotesTopicPapers
BRCA2 13q12.3 FAD, FACD, FAD1, GLM3, BRCC2, FANCD, PNCA2, FANCD1, XRCC11, BROVCA2 -BRCA2 and Breast Cancer
-Prophylactic Treatments for Women with BRCA1/BRAC2 mutations
-BRCA2 and Breast Cancer During Pregnancy
-BRCA2 and Outcome in Breast Cancer
3000
BRCA1 17q21 IRIS, PSCP, BRCAI, BRCC1, FANCS, PNCA4, RNF53, BROVCA1, PPP1R53 Germline
-185delAG mutation (c.68_69delAG) in BRCA1
-Prophylactic Treatments for Women with BRCA1/BRAC2 mutations
-BRCA1 mutations in Breast Cancer
3000
MKI67 10q26.2 KIA, MIB-, MIB-1, PPP1R105 -MKI67 and Breast Cancer
1780
TP53 17p13.1 P53, BCC7, LFS1, TRP53 -TP53 mutations in Breast Cancer
1464
ERBB2 17q12 NEU, NGL, HER2, TKR1, CD340, HER-2, MLN 19, HER-2/neu Gene Amplification
-HER2 and Breast Cancer
784
CCND1 11q13 BCL1, PRAD1, U21B31, D11S287E -CCND1 and Breast Cancer
614
NODAL 10q22.1 HTX5 -NODAL and Breast Cancer
491
MUC1 1q21 EMA, MCD, PEM, PUM, KL-6, MAM6, MCKD, PEMT, CD227, H23AG, MCKD1, MUC-1, ADMCKD, ADMCKD1, CA 15-3, MUC-1/X, MUC1/ZD, MUC-1/SEC Prognostic
-MUC1 Expression in Breast Cancer
465
CYP19A1 15q21.1 ARO, ARO1, CPV1, CYAR, CYP19, CYPXIX, P-450AROM -CYP19A1 and Breast Cancer
432
PTEN 10q23.3 BZS, DEC, CWS1, GLM2, MHAM, TEP1, MMAC1, PTEN1, 10q23del -PTEN and Breast Cancer
412
AKT1 14q32.32 AKT, PKB, RAC, CWS6, PRKBA, PKB-ALPHA, RAC-ALPHA -AKT1 and Breast Cancer
344
PROC 2q13-q14 PC, APC, PROC1, THPH3, THPH4 -PROC and Breast Cancer
342
AR Xq12 KD, AIS, TFM, DHTR, SBMA, HYSP1, NR3C4, SMAX1, HUMARA -AR and Breast Cancer
307
ABCB1 7q21.12 CLCS, MDR1, P-GP, PGY1, ABC20, CD243, GP170 -ABCB1 and Breast Cancer
295
BIRC5 17q25 API4, EPR-1 -BIRC5 and Breast Cancer
288
SRC 20q12-q13 ASV, SRC1, c-SRC, p60-Src -SRC and Breast Cancer
278
KITLG 12q22 SF, MGF, SCF, FPH2, FPHH, KL-1, Kitl, SHEP7 -KITLG and Breast Cancer
274
CDKN1A 6p21.2 P21, CIP1, SDI1, WAF1, CAP20, CDKN1, MDA-6, p21CIP1 -CDKN1A and Breast Cancer
263
CTNNB1 3p21 CTNNB, MRD19, armadillo -CTNNB1 and Breast Cancer
251
CHEK2 22q12.1 CDS1, CHK2, LFS2, RAD53, hCds1, HuCds1, PP1425 -CHEK2 and Breast Cancer
246
MYC 8q24.21 MRTL, MYCC, c-Myc, bHLHe39 -MYC and Breast Cancer
240
CDKN2A 9p21 ARF, MLM, P14, P16, P19, CMM2, INK4, MTS1, TP16, CDK4I, CDKN2, INK4A, MTS-1, P14ARF, P19ARF, P16INK4, P16INK4A, P16-INK4A -CDKN2A and Breast Cancer
238
ESR1 6q25.1 ER, ESR, Era, ESRA, ESTRR, NR3A1 -ESR1 and Breast Cancer
237
PTGS2 1q25.2-q25.3 COX2, COX-2, PHS-2, PGG/HS, PGHS-2, hCox-2, GRIPGHS -PTGS2 (COX2) and Breast Cancer
-COX2 Inhibitors for Breast Cancer
150
CD44 11p13 IN, LHR, MC56, MDU2, MDU3, MIC4, Pgp1, CDW44, CSPG8, HCELL, HUTCH-I, ECMR-III -CD44 and Breast Cancer
234
TNF 6p21.3 DIF, TNFA, TNFSF2, TNF-alpha -TNF and Breast Cancer
232
ATM 11q22-q23 AT1, ATA, ATC, ATD, ATE, ATDC, TEL1, TELO1 -ATM and Breast Cancer
216
BAX 19q13.3-q13.4 BCL2L4 -BAX and Breast Cancer
215
TOP1 20q12-q13.1 TOPI -TOP1 and Breast Cancer
207
MET 7q31 HGFR, AUTS9, RCCP2, c-Met -C-MET and Triple Negative Breast Cancer
-C-MET and Breast Cancer
-Proto-Oncogene Proteins c-met and Triple Negative Breast Cancer
186
RAD51 15q15.1 RECA, BRCC5, MRMV2, HRAD51, RAD51A, HsRad51, HsT16930 -RAD51 and Breast Cancer
197
PIK3CA 3q26.3 MCM, CWS5, MCAP, PI3K, CLOVE, MCMTC, p110-alpha -PIK3CA and Breast Cancer
197
CYP2D6 22q13.1 CPD6, CYP2D, CYP2DL1, CYPIID6, P450C2D, P450DB1, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, P450-DB1 -CYP2D6 and Breast Cancer
196
MTOR 1p36.2 FRAP, FRAP1, FRAP2, RAFT1, RAPT1 -MTOR and Breast Cancer
187
GSTP1 11q13 PI, DFN7, GST3, GSTP, FAEES3, HEL-S-22 -GSTP1 and Breast Cancer
185
MDM2 12q14.3-q15 HDMX, hdm2, ACTFS -MDM2 and Breast Cancer
170
KLK3 19q13.41 APS, PSA, hK3, KLK2A1 -PSA expression in Breast Cancer
169
CYP1A1 15q24.1 AHH, AHRR, CP11, CYP1, P1-450, P450-C, P450DX -CYP1A1 and Breast Cancer
168
CDH1 16q22.1 UVO, CDHE, ECAD, LCAM, Arc-1, CD324 -CDH1 and Breast Cancer
166
FGFR2 10q26 BEK, JWS, BBDS, CEK3, CFD1, ECT1, KGFR, TK14, TK25, BFR-1, CD332, K-SAM -FGFR2 and Breast Cancer
161
CDKN1B 12p13.1-p12 KIP1, MEN4, CDKN4, MEN1B, P27KIP1 Prognostic
-CDKN1B and Breast Cancer
158
PPARG 3p25 GLM1, CIMT1, NR1C3, PPARG1, PPARG2, PPARgamma -PPARG and Breast Cancer
151
MMP2 16q12.2 CLG4, MONA, CLG4A, MMP-2, TBE-1, MMP-II -MMP2 and Breast Cancer
146
TIMP1 Xp11.3-p11.23 EPA, EPO, HCI, CLGI, TIMP -TIMP1 and Breast Cancer
145
HIF1A 14q23.2 HIF1, MOP1, PASD8, HIF-1A, bHLHe78, HIF-1alpha, HIF1-ALPHA -HIF1A and Breast Cancer
143
FOS 14q24.3 p55, AP-1, C-FOS -FOS and Breast Cancer
142
TFF1 21q22.3 pS2, BCEI, HPS2, HP1.A, pNR-2, D21S21 -TFF1 and Breast Cancer
138
GSTM1 1p13.3 MU, H-B, GST1, GTH4, GTM1, MU-1, GSTM1-1, GSTM1a-1a, GSTM1b-1b -GSTM1 and Breast Cancer
137
CXCR4 2q21 FB22, HM89, LAP3, LCR1, NPYR, WHIM, CD184, LAP-3, LESTR, NPY3R, NPYRL, WHIMS, HSY3RR, NPYY3R, D2S201E -CXCR4 and Breast Cancer
129
STAT3 17q21.31 APRF, HIES, ADMIO -STAT3 and Breast Cancer
127
VEGFA 6p12 VPF, VEGF, MVCD1 -VEGFA and Breast Cancer
127
CYP1B1 2p22.2 CP1B, GLC3A, CYPIB1, P4501B1 -CYP1B1 and Breast Cancer
126
CD24 6q21 CD24A -CD24 and Breast Cancer
126
BLID 11q24.1 BRCC2 -BLID and Breast Cancer
124
TGFB1 19q13.1 CED, LAP, DPD1, TGFB, TGFbeta -TGFB1 and Breast Cancer
123
BCL2 18q21.3 Bcl-2, PPP1R50 -BCL2 and Breast Cancer
122
IGF1R 15q26.3 IGFR, CD221, IGFIR, JTK13 -IGF1R and Breast Cancer
120
CASP8 2q33-q34 CAP4, MACH, MCH5, FLICE, ALPS2B, Casp-8 -CASP8 and Breast Cancer
119
CAMP 3p21.3 LL37, CAP18, CRAMP, HSD26, CAP-18, FALL39, FALL-39 -CAMP and Breast Cancer
116
COMT 22q11.21 HEL-S-98n -COMT and Breast Cancer
115
CISH 3p21.3 CIS, G18, SOCS, CIS-1, BACTS2 -CISH and Breast Cancer
112
TOP2A 17q21-q22 TOP2, TP2A -TOP2A and Breast Cancer
108
FLCN 17p11.2 BHD, FLCL -FLCN and Breast Cancer
107
XRCC1 19q13.2 RCC -XRCC1 and Breast Cancer
107
PCNA 20pter-p12 ATLD2 -PCNA and Breast Cancer
104
PARP1 1q41-q42 PARP, PPOL, ADPRT, ARTD1, ADPRT1, PARP-1, ADPRT 1, pADPRT-1 -PARP1 and Breast Cancer
100
NOTCH1 9q34.3 hN1, AOS5, TAN1, AOVD1 -NOTCH1 and Breast Cancer
99
GSTT1 22q11.23 -GSTT1 Polymorphisms and Breast Cancer
96
TUBE1 6q21 TUBE, dJ142L7.2 -TUBE1 and Breast Cancer
94
CXCL12 10q11.1 IRH, PBSF, SDF1, TLSF, TPAR1, SCYB12 -CXCL12 and Breast Cancer
91
CYP17A1 10q24.3 CPT7, CYP17, S17AH, P450C17 -CYP17A1 and Breast Cancer
90
ABCG2 4q22 MRX, MXR, ABCP, BCRP, BMDP, MXR1, ABC15, BCRP1, CD338, GOUT1, CDw338, UAQTL1, EST157481 -ABCG2 and Breast Cancer
86
RASSF1 3p21.3 123F2, RDA32, NORE2A, RASSF1A, REH3P21 -RASSF1 and Breast Cancer
86
CDK2 12q13 CDKN2, p33(CDK2) -CDK2 and Breast Cancer
85
TGFBR1 9q22 AAT5, ALK5, ESS1, LDS1, MSSE, SKR4, ALK-5, LDS1A, LDS2A, TGFR-1, ACVRLK4, tbetaR-I -TGFBR1 and Breast Cancer
85
CDK4 12q14 CMM3, PSK-J3 -CDK4 and Breast Cancer
84
FOXA1 14q21.1 HNF3A, TCF3A -FOXA1 and Breast Cancer
80
BARD1 2q34-q35 -BARD1 and Breast Cancer
80
GATA3 10p15 HDR, HDRS -GATA3 and Breast Cancer
80
BAD 11q13.1 BBC2, BCL2L8 -BAD and Breast Cancer
79
E2F1 20q11.2 RBP3, E2F-1, RBAP1, RBBP3 -E2F1 and Breast Cancer
78
NME1 17q21.3 NB, AWD, NBS, GAAD, NDKA, NM23, NDPKA, NDPK-A, NM23-H1 -NME1 and Breast Cancer
77
ERBB3 12q13 HER3, LCCS2, ErbB-3, c-erbB3, erbB3-S, MDA-BF-1, c-erbB-3, p180-ErbB3, p45-sErbB3, p85-sErbB3 -ERBB3 and Breast Cancer
76
ETS1 11q23.3 p54, ETS-1, EWSR2 -ETS1 and Breast Cancer
75
SMAD3 15q22.33 LDS3, LDS1C, MADH3, JV15-2, HSPC193, HsT17436 -SMAD3 and Breast Cancer
75
CYP3A4 7q21.1 HLP, CP33, CP34, CYP3A, NF-25, CYP3A3, P450C3, CYPIIIA3, CYPIIIA4, P450PCN1 -CYP3A4 and Breast Cancer
73
SERPINE1 7q22.1 PAI, PAI1, PAI-1, PLANH1 -SERPINE1 and Breast Cancer
73
SULT1A1 16p12.1 PST, STP, STP1, P-PST, ST1A1, ST1A3, TSPST1, HAST1/HAST2 -SULT1A1 and Breast Cancer
73
JUN 1p32-p31 AP1, AP-1, c-Jun -c-Jun and Breast Cancer
72
RHOC 1p13.1 H9, ARH9, ARHC, RHOH9 -RHOC and Breast Cancer
72
TERT 5p15.33 TP2, TRT, CMM9, EST2, TCS1, hTRT, DKCA2, DKCB4, hEST2, PFBMFT1 -TERT and Breast Cancer
72
MIR21 17q23.1 MIRN21, miR-21, miRNA21, hsa-mir-21 -MicroRNA miR-21 and Breast Cancer
71
RB1 13q14.2 RB, pRb, OSRC, pp110, p105-Rb, PPP1R130 -RB1 mutations in Breast Cancer
69
TGFA 2p13 TFGA -TGFA and Breast Cancer
69
FLT1 13q12 FLT, FLT-1, VEGFR1, VEGFR-1 -FLT1 and Breast Cancer
68
XRCC3 14q32.3 CMM6 -XRCC3 and Breast Cancer
68
CCNB1 5q12 CCNB -CCNB1 and Breast Cancer
68
FGFR1 8p11.23-p11.22 CEK, FLG, HH2, OGD, FLT2, KAL2, BFGFR, CD331, FGFBR, FLT-2, HBGFR, N-SAM, FGFR-1, HRTFDS, bFGF-R-1 -FGFR1 and Breast Cancer
68
PDLIM4 5q31.1 RIL -PDLIM4 and Breast Cancer
68
SCGB2A2 11q13 MGB1, UGB2 -SCGB2A2 and Breast Cancer
67
CEACAM5 19q13.1-q13.2 CEA, CD66e -CEACAM5 and Breast Cancer
67
BCL2L1 20q11.21 BCLX, BCL2L, BCLXL, BCLXS, Bcl-X, bcl-xL, bcl-xS, PPP1R52, BCL-XL/S -BCL2L1 and Breast Cancer
67
IGFBP3 7p12.3 IBP3, BP-53 -IGFBP3 and Breast Cancer
67
TWIST1 7p21.2 CRS, CSO, SCS, ACS3, CRS1, BPES2, BPES3, TWIST, bHLHa38 -TWIST1 and Breast Cancer
66
AKT2 19q13.1-q13.2 PKBB, PRKBB, HIHGHH, PKBBETA, RAC-BETA -AKT2 and Breast Cancer
65
HRAS 11p15.5 CTLO, HAMSV, HRAS1, RASH1, p21ras, C-H-RAS, H-RASIDX, C-BAS/HAS, C-HA-RAS1 -HRAS and Breast Cancer
65
FGF3 11q13 INT2, HBGF-3 -FGF3 and Breast Cancer
62
FGF2 4q26 BFGF, FGFB, FGF-2, HBGF-2 -FGF2 and Breast Cancer
62
CYP3A5 7q21.1 CP35, PCN3, CYPIIIA5, P450PCN3 -CYP3A5 and Breast Cancer
61
NAT2 8p22 AAC2, PNAT, NAT-2 -NAT2 and Breast Cancer
61
MYB 6q22-q23 efg, Cmyb, c-myb, c-myb_CDS -MYB and Breast Cancer
60
BRAP 12q24 IMP, BRAP2, RNF52 -BRAP and Breast Cancer
59
IGF2R 6q26 MPR1, MPRI, CD222, CIMPR, M6P-R -IGF2R and Breast Cancer
57
AURKA 20q13 AIK, ARK1, AURA, BTAK, STK6, STK7, STK15, AURORA2, PPP1R47 -AURKA and Breast Cancer
57
TTPA 8q12.3 ATTP, AVED, TTP1, alphaTTP -TTPA and Breast Cancer
57
MAP3K1 5q11.2 MEKK, MEKK1, SRXY6, MEKK 1, MAPKKK1 -MAP3K1 and Breast Cancer
55
NCOA3 20q12 ACTR, AIB1, RAC3, SRC3, pCIP, AIB-1, CTG26, SRC-3, CAGH16, KAT13B, TNRC14, TNRC16, TRAM-1, bHLHe42 -NCOA3 and Breast Cancer
54
NBN 8q21 ATV, NBS, P95, NBS1, AT-V1, AT-V2 -NBN and Breast Cancer
54
ACHE 7q22 YT, ACEE, ARACHE, N-ACHE -ACHE and Breast Cancer
53
ERCC2 19q13.3 EM9, TTD, XPD, COFS2, TFIIH -ERCC2 and Breast Cancer
53
EZH2 7q35-q36 WVS, ENX1, EZH1, KMT6, WVS2, ENX-1, EZH2b, KMT6A -EZH2 and Breast Cancer
52
IGF2 11p15.5 IGF-II, PP9974, C11orf43 -IGF2 and Breast Cancer
52
RHOA 3p21.3 ARHA, ARH12, RHO12, RHOH12 -RHOA and Breast Cancer
52
IL6 7p21 HGF, HSF, BSF2, IL-6, IFNB2 -IL6 and Breast Cancer
51
RELA 11q13 p65, NFKB3 -RELA and Breast Cancer
51
TFAP2A 6p24 AP-2, BOFS, AP2TF, TFAP2, AP-2alpha -TFAP2A Expression in Breast Cancer
51
TFAP2B 6p12 AP-2B, AP2-B -TFAP2B and Breast Cancer
50
TFAP2C 20q13.2 ERF1, TFAP2G, hAP-2g, AP2-GAMMA -TFAP2C and Breast Cancer
50
ZEB1 10p11.2 BZP, TCF8, AREB6, FECD6, NIL2A, PPCD3, ZFHEP, ZFHX1A, DELTAEF1 -ZEB1 and Breast Cancer
50
FH 1q42.1 MCL, FMRD, LRCC, HLRCC, MCUL1 -FH and Breast Cancer
50
RAC1 7p22 MIG5, Rac-1, TC-25, p21-Rac1 -RAC1 and Breast Cancer
49
HSD17B2 16q24.1-q24.2 HSD17, SDR9C2, EDH17B2 -HSD17B2 and Breast Cancer
49
SMAD4 18q21.1 JIP, DPC4, MADH4, MYHRS -SMAD4 and Breast Cancer
48
WNT1 12q13 INT1, OI15, BMND16 -WNT1 and Breast Cancer
48
ITGB1 10p11.2 CD29, FNRB, MDF2, VLAB, GPIIA, MSK12, VLA-BETA -ITGB1 (CD29) and Breast Cancer
47
RAD50 5q31 NBSLD, RAD502, hRad50 -RAD50 and Breast Cancer
47
DNMT1 19p13.2 AIM, DNMT, MCMT, CXXC9, HSN1E, ADCADN -DNMT1 and Breast Cancer
46
H2AFX 11q23.3 H2AX, H2A.X, H2A/X -H2AFX and Breast Cancer
46
STK11 19p13.3 PJS, LKB1, hLKB1 -STK11 and Breast Cancer
45
TNFRSF11A 18q22.1 FEO, OFE, ODFR, OSTS, PDB2, RANK, CD265, OPTB7, TRANCER, LOH18CR1 -TNFRSF11A and Breast Cancer
45
EPCAM 2p21 ESA, KSA, M4S1, MK-1, DIAR5, EGP-2, EGP40, KS1/4, MIC18, TROP1, EGP314, HNPCC8, TACSTD1 -EPCAM and Breast Cancer
45
SHBG 17p13.1 ABP, SBP, TEBG -SHBG and Breast Cancer
45
HGF 7q21.1 SF, HGFB, HPTA, F-TCF, DFNB39 -HGF and Breast Cancer
44
LSP1 11p15.5 WP34, pp52 -LSP1 and Breast Cancer
43
RAD51C 17q22 FANCO, R51H3, BROVCA3, RAD51L2 -RAD51C and Breast Cancer
43
HDAC1 1p34 HD1, RPD3, GON-10, RPD3L1 -HDAC1 and Breast Cancer
43
NQO1 16q22.1 DTD, QR1, DHQU, DIA4, NMOR1, NMORI -NQO1 and Breast Cancer
42
IGF1 12q23.2 IGFI, IGF-I, IGF1A -IGF1 and Breast Cancer
42
ABCC1 16p13.1 MRP, ABCC, GS-X, MRP1, ABC29 -ABCC1 (MRP1) and Breast Cancer
42
GRB7 17q12 -GRB7 and Breast Cancer
42
TOX3 16q12.1 CAGF9, TNRC9 -TOX3 and Breast Cancer
41
TNFRSF10B 8p22-p21 DR5, CD262, KILLER, TRICK2, TRICKB, ZTNFR9, TRAILR2, TRICK2A, TRICK2B, TRAIL-R2, KILLER/DR5 -TNFRSF10B and Breast Cancer
41
GAPDH 12p13 G3PD, GAPD, HEL-S-162eP -GAPDH and Breast Cancer
41
ERBB4 2q33.3-q34 HER4, ALS19, p180erbB4 -ERBB4 and Breast Cancer
40
CDC42 1p36.1 G25K, CDC42Hs -CDC42 and Breast Cancer
40
TGFBR2 3p22 AAT3, FAA3, LDS2, MFS2, RIIC, LDS1B, LDS2B, TAAD2, TGFR-2, TGFbeta-RII -TGFBR2 and Breast Cancer
40
SOD2 6q25.3 IPOB, MNSOD, MVCD6 -SOD2 and Breast Cancer
39
NTRK3 15q25 TRKC, gp145(trkC) Translocation
-NTRK3 and Breast Cancer
-t(12;15)(p13;q25) ETV6-NTRK3 in Breast Cancer
33
KRT5 12q13.13 K5, CK5, DDD, DDD1, EBS2, KRT5A -KRT5 and Breast Cancer
39
STAT1 2q32.2 CANDF7, IMD31A, IMD31B, IMD31C, ISGF-3, STAT91 -STAT1 and Breast Cancer
39
VEGFC 4q34.3 VRP, Flt4-L, LMPH1D -VEGFC and Breast Cancer
38
CYP2C19 10q24 CPCJ, CYP2C, P450C2C, CYPIIC17, CYPIIC19, P450IIC19 -CYP2C19 and Breast Cancer
37
CYP1A2 15q24.1 CP12, P3-450, P450(PA) -CYP1A2 and Breast Cancer
37
CAV1 7q31.1 CGL3, PPH3, BSCL3, LCCNS, VIP21, MSTP085 -CAV1 and Breast Cancer
36
BACH1 21q22.11 BACH-1, BTBD24 -BACH1 and Breast Cancer
35
CCND2 12p13 MPPH3, KIAK0002 -CCND2 and Breast Cancer
35
PARL 3q27.1 PSARL, PSARL1, RHBDS1, PRO2207, PSENIP2 -PARL and Breast Cancer
35
BRMS1 11q13.2 -BRMS1 and Breast Cancer
35
ALDH1A1 9q21.13 ALDC, ALDH1, HEL-9, HEL12, PUMB1, ALDH11, RALDH1, ALDH-E1, HEL-S-53e -ALDH1A1 and Breast Cancer
34
OLAH 10p13 SAST, AURA1, THEDC1 -OLAH and Breast Cancer
34
PRLR 5p13.2 HPRL, MFAB, hPRLrI -PRLR and Breast Cancer
33
CXCL1 4q21 FSP, GRO1, GROa, MGSA, NAP-3, SCYB1, MGSA-a -CXCL1 and Breast Cancer
32
PDGFB 22q13.1 SIS, SSV, IBGC5, PDGF2, c-sis, PDGF-2 -PDGFB and Breast Cancer
32
SMAD2 18q21.1 JV18, MADH2, MADR2, JV18-1, hMAD-2, hSMAD2 -SMAD2 and Breast Cancer
32
FAS 10q24.1 APT1, CD95, FAS1, APO-1, FASTM, ALPS1A, TNFRSF6 -FAS and Breast Cancer
31
BAG1 9p12 HAP, BAG-1, RAP46 Overexpression
-BAG1 overexpression in Breast Cancer
31
PTK2 8q24.3 FAK, FADK, FAK1, FRNK, PPP1R71, p125FAK, pp125FAK -PTK2 and Breast Cancer
31
FOXM1 12p13 MPP2, TGT3, HFH11, HNF-3, INS-1, MPP-2, PIG29, FKHL16, FOXM1B, HFH-11, TRIDENT, MPHOSPH2 -FOXM1 and Breast Cancer
31
S100A4 1q21 42A, 18A2, CAPL, FSP1, MTS1, P9KA, PEL98 -S100A4 and Breast Cancer
31
XRCC2 7q36.1 -XRCC2 and Breast Cancer
31
IRS1 2q36 HIRS-1 -IRS1 and Breast Cancer
31
CTCF 16q21-q22.3 MRD21 -CTCF and Breast Cancer
31
TNFSF11 13q14 ODF, OPGL, sOdf, CD254, OPTB2, RANKL, TRANCE, hRANKL2 -TNFSF11 and Breast Cancer
30
AREG 4q13.3 AR, SDGF, AREGB, CRDGF -AREG and Breast Cancer
30
SFRP1 8p11.21 FRP, FRP1, FrzA, FRP-1, SARP2 -SFRP1 and Breast Cancer
30
LIMK1 7q11.23 LIMK, LIMK-1 -LIMK1 and Breast Cancer
30
EGR1 5q31.1 TIS8, AT225, G0S30, NGFI-A, ZNF225, KROX-24, ZIF-268 -EGR1 and Breast Cancer
30
CCNE1 19q12 CCNE -CCNE1 and Breast Cancer
30
GPER1 7p22.3 mER, CEPR, GPER, DRY12, FEG-1, GPR30, LERGU, LyGPR, CMKRL2, LERGU2, GPCR-Br -GPER and Breast Cancer
30
MTA1 14q32.3 -MTA1 and Breast Cancer
30
EIF4E 4q23 CBP, EIF4F, AUTS19, EIF4E1, EIF4EL1 -EIF4E and Breast Cancer
30
ANXA8 10q11.22 ANX8, CH17-360D5.2 -ANXA8 and Breast Cancer
30
CHIA 1p13.2 CHIT2, AMCASE, TSA1902 -CHIA and Breast Cancer
29
MMP3 11q22.3 SL-1, STMY, STR1, CHDS6, MMP-3, STMY1 -MMP3 and Breast Cancer
29
FOXP3 Xp11.23 JM2, AIID, IPEX, PIDX, XPID, DIETER -FOXP3 and Breast Cancer
29
CD82 11p11.2 R2, 4F9, C33, IA4, ST6, GR15, KAI1, SAR2, TSPAN27 -CD82 and Breast Cancer
29
CDC25A 3p21 CDC25A2 -CDC25A and Breast Cancer
28
TIMP2 17q25 DDC8, CSC-21K Prognostic
-TIMP2 Expression in Breast Cancer
28
JUNB 19p13.2 AP-1 -JUNB and Breast Cancer
28
MMP1 11q22.3 CLG, CLGN -MMP1 and Breast Cancer
28
SOX2 3q26.3-q27 ANOP3, MCOPS3 -SOX2 and Breast Cancer
28
MDM4 1q32 HDMX, MDMX, MRP1 -MDM4 and Breast Cancer
28
WWOX 16q23 FOR, WOX1, EIEE28, FRA16D, SCAR12, HHCMA56, PRO0128, SDR41C1, D16S432E -WWOX and Breast Cancer
28
FOXO3 6q21 FOXO2, AF6q21, FKHRL1, FOXO3A, FKHRL1P2 -FOXO3 and Breast Cancer
28
NCOA1 2p23 SRC1, KAT13A, RIP160, F-SRC-1, bHLHe42, bHLHe74 -NCOA1 and Breast Cancer
28
DROSHA 5p13.3 RN3, ETOHI2, RNASEN, RANSE3L, RNASE3L, HSA242976 -DROSHA and Breast Cancer
28
PPP2CB 8p12 PP2CB, PP2Abeta -PPP2CB and Breast Cancer
27
COIL 17q22 CLN80, p80-coilin -COIL and Breast Cancer
27
JUND 19p13.2 AP-1 -JUND and Breast Cancer
27
PPP2CA 5q31.1 RP-C, PP2Ac, PP2CA, PP2Calpha -PPP2CA and Breast Cancer
27
CTGF 6q23.1 CCN2, NOV2, HCS24, IGFBP8 -CTGF and Breast Cancer
27
PLAUR 19q13 CD87, UPAR, URKR, U-PAR -PLAUR and Breast Cancer
27
XPC 3p25.1 XP3, RAD4, XPCC, p125 -XPC and Breast Cancer
26
TCF4 18q21.1 E2-2, ITF2, PTHS, SEF2, ITF-2, SEF-2, TCF-4, SEF2-1, SEF2-1A, SEF2-1B, SEF2-1D, bHLHb19 -TCF4 and Breast Cancer
26
THBS1 15q15 TSP, THBS, TSP1, TSP-1, THBS-1 -THBS1 and Breast Cancer
26
PIN1 19p13 DOD, UBL5 -PIN1 and Breast Cancer
26
GRB2 17q24-q25 ASH, Grb3-3, MST084, NCKAP2, MSTP084, EGFRBP-GRB2 -GRB2 and Breast Cancer
26
CYP2C9 10q24 CPC9, CYP2C, CYP2C10, CYPIIC9, P450IIC9 -CYP2C9 and Breast Cancer
26
MCAM 11q23.3 CD146, MUC18 -MCAM and Breast Cancer
26
PRKCA 17q22-q23.2 AAG6, PKCA, PRKACA, PKC-alpha -PRKCA and Breast Cancer
26
DNMT3B 20q11.2 ICF, ICF1, M.HsaIIIB -DNMT3B and Breast Cancer
26
MAF 16q22-q23 CCA4, c-MAF, CTRCT21 -MAF and Breast Cancer
26
TERC 3q26 TR, hTR, TRC3, DKCA1, PFBMFT2, SCARNA19 -TERC and Breast Cancer
26
STAR 8p11.2 STARD1 -STAR and Breast Cancer
25
LGALS3 14q22.3 L31, GAL3, MAC2, CBP35, GALBP, GALIG, LGALS2 -LGALS3 and Breast Cancer
25
MMP11 22q11.23 ST3, SL-3, STMY3 Prognostic
-MMP11 Expression in Breast Cancer
25
ZEB2 2q22.3 SIP1, SIP-1, ZFHX1B, HSPC082, SMADIP1 -ZEB2 and Breast Cancer
25
FGF4 11q13.3 HST, KFGF, HST-1, HSTF1, K-FGF, HBGF-4 -FGF4 and Breast Cancer
25
SKP2 5p13 p45, FBL1, FLB1, FBXL1 -SKP2 and Breast Cancer
25
PECAM1 17q23.3 CD31, PECA1, GPIIA', PECAM-1, endoCAM, CD31/EndoCAM -PECAM1 and Breast Cancer
24
TSG101 11p15 TSG10, VPS23 -TSG101 and Breast Cancer
24
BCAR1 16q23.1 CAS, CAS1, CASS1, CRKAS, P130Cas -BCAR1 and Breast Cancer
24
SIRT1 10q21.3 SIR2, hSIR2, SIR2L1 -SIRT1 and Breast Cancer
24
FOXO1 13q14.1 FKH1, FKHR, FOXO1A -FOXO1 and Breast Cancer
24
NRG1 8p12 GGF, HGL, HRG, NDF, ARIA, GGF2, HRG1, HRGA, SMDF, MST131, MSTP131, NRG1-IT2 -NRG1 and Breast Cancer
24
ZNF217 20q13.2 ZABC1 -ZNF217 and Breast Cancer
24
SPARC 5q31.3-q32 ON -SPARC and Breast Cancer
24
TIMP3 22q12.3 SFD, K222, K222TA2, HSMRK222 -TIMP3 and Breast Cancer
24
SYK 9q22 p72-Syk -SYK and Breast Cancer
24
BECN1 17q21 ATG6, VPS30, beclin1 -BECN1 and Breast Cancer
24
ESR2 14q23.2 Erb, ESRB, ESTRB, NR3A2, ER-BETA, ESR-BETA -ESR2 and Breast Cancer
24
CYP2B6 19q13.2 CPB6, EFVM, IIB1, P450, CYP2B, CYP2B7, CYP2B7P, CYPIIB6 -CYP2B6 and Breast Cancer
24
CLOCK 4q12 KAT13D, bHLHe8 -CLOCK and Breast Cancer
23
CASP7 10q25 MCH3, CMH-1, LICE2, CASP-7, ICE-LAP3 -CASP7 and Breast Cancer
23
SCGB3A1 5q35.3 HIN1, HIN-1, LU105, UGRP2, PnSP-2 -SCGB3A1 and Breast Cancer
23
TYMS 18p11.32 TS, TMS, HST422 -TYMS and Breast Cancer
23
TP63 3q28 AIS, KET, LMS, NBP, RHS, p40, p51, p63, EEC3, OFC8, p73H, p73L, SHFM4, TP53L, TP73L, p53CP, TP53CP, B(p51A), B(p51B) -TP63 and Breast Cancer
23
HSD17B1 17q11-q21 HSD17, EDHB17, EDH17B2, SDR28C1 -HSD17B1 and Breast Cancer
23
FGFR4 5q35.2 TKF, JTK2, CD334 -FGFR4 and Breast Cancer
23
SLC2A1 1p34.2 PED, DYT9, GLUT, DYT17, DYT18, EIG12, GLUT1, HTLVR, GLUT-1, GLUT1DS -GLUT1 expression in Breast Cancer
23
PAK1 11q13-q14 PAKalpha -PAK1 and Breast Cancer
23
HEBP1 12p13.1 HBP, HEBP -HEBP1 and Breast Cancer
22
NAT1 8p22 AAC1, MNAT, NATI, NAT-1 -NAT1 and Breast Cancer
22
BUB1 2q14 BUB1A, BUB1L, hBUB1 -BUB1 and Breast Cancer
22
E2F4 16q22.1 E2F-4 -E2F4 and Breast Cancer
22
CCNA2 4q27 CCN1, CCNA -CCNA2 and Breast Cancer
22
KISS1 1q32 HH13, KiSS-1 -KISS1 and Breast Cancer
22
SNCG 10q23.2-q23.3 SR, BCSG1 -SNCG and Breast Cancer
22
WNT5A 3p21-p14 hWNT5A -WNT5A and Breast Cancer
22
STAT5A 17q11.2 MGF, STAT5 -STAT5A and Breast Cancer
22
ARHGEF1 19q13.13 LSC, GEF1, LBCL2, SUB1.5, P115-RHOGEF -ARHGEF1 and Breast Cancer
22
NFE2L2 2q31 NRF2 -NFE2L2 and Breast Cancer
22
PLK1 16p12.2 PLK, STPK13 -PLK1 and Breast Cancer
22
PDCD4 10q24 H731 -PDCD4 and Breast Cancer
22
CCL2 17q11.2-q12 HC11, MCAF, MCP1, MCP-1, SCYA2, GDCF-2, SMC-CF, HSMCR30 -CCL2 and Breast Cancer
22
TP53BP1 15q15-q21 p202, 53BP1 -TP53BP1 and Breast Cancer
22
RUNX2 6p21 CCD, AML3, CCD1, CLCD, OSF2, CBFA1, OSF-2, PEA2aA, PEBP2aA, CBF-alpha-1 -RUNX2 and Breast Cancer
22
PTHLH 12p12.1-p11.2 HHM, PLP, BDE2, PTHR, PTHRP -PTHLH and Breast Cancer
21
MIB1 18q11.2 MIB, DIP1, ZZZ6, DIP-1, LVNC7, ZZANK2 -MIB1 and Breast Cancer
21
CST6 11q13 -CST6 and Breast Cancer
21
RAD52 12p13-p12.2 -RAD52 and Breast Cancer
21
KLF4 9q31 EZF, GKLF -KLF4 and Breast Cancer
21
CDK1 10q21.1 CDC2, CDC28A, P34CDC2 -CDK1 and Breast Cancer
21
TRPM2 21q22.3 KNP3, EREG1, TRPC7, LTRPC2, NUDT9H, NUDT9L1 -TRPM2 and Breast Cancer
21
MTDH 8q22.1 3D3, AEG1, AEG-1, LYRIC, LYRIC/3D3 -MTDH and Breast Cancer
21
NOTCH2 1p13-p11 hN2, AGS2, HJCYS -NOTCH2 and Breast Cancer
21
RAP1A 1p13.3 RAP1, C21KG, G-22K, KREV1, KREV-1, SMGP21 -Breast Cancer and RAP1A
21
MIR126 9q34.3 MIRN126, mir-126, miRNA126 -MicroRNA mir-126 and Breast Cancer
21
DIRAS3 1p31 ARHI, NOEY2 -DIRAS3 and Breast Cancer
21
NCOR1 17p11.2 N-CoR, TRAC1, N-CoR1, hN-CoR, PPP1R109 -NCOR1 and Breast Cancer
20
ELAVL1 19p13.2 HUR, Hua, MelG, ELAV1 -ELAVL1 and Breast Cancer
20
LEPR 1p31 OBR, OB-R, CD295, LEP-R, LEPRD -LEPR and Breast Cancer
20
NANOG 12p13.31 -NANOG and Breast Cancer
20
OSCAR 19q13.42 PIGR3, PIgR-3 -OSCAR and Breast Cancer
20
EPHA2 1p36 ECK, CTPA, ARCC2, CTPP1, CTRCT6 -EPHA2 and Breast Cancer
20
CRK 17p13.3 p38, CRKII -CRK and Breast Cancer
20
LOX 5q23.2 -LOX and Breast Cancer
20
FTCDNL1 2q33.1 FONG -FONG and Breast Cancer
20
FBXW7 4q31.3 AGO, CDC4, FBW6, FBW7, hAgo, FBX30, FBXW6, SEL10, hCdc4, FBXO30, SEL-10 -FBXW7 and Breast Cancer
20
EP300 22q13.2 p300, KAT3B, RSTS2 -EP300 and Breast Cancer
20
PTK6 20q13.3 BRK -PTK6 and Breast Cancer
20
TFF3 21q22.3 ITF, P1B, TFI -TFF3 and Breast Cancer
20
POLE 12q24.3 FILS, POLE1, CRCS12 -POLE and Breast Cancer
19
TNFRSF11B 8q24 OPG, TR1, OCIF -TNFRSF11B and Breast Cancer
19
PPM1D 17q23.2 WIP1, PP2C-DELTA -PPM1D and Breast Cancer
19
CYP24A1 20q13 CP24, HCAI, CYP24, P450-CC24 -CYP24A1 and Breast Cancer
19
SPP1 4q22.1 OPN, BNSP, BSPI, ETA-1 -SPP1 and Breast Cancer
19
HMOX1 22q13.1 HO-1, HSP32, HMOX1D, bK286B10 -HMOX1 and Breast Cancer
19
MRE11A 11q21 ATLD, HNGS1, MRE11, MRE11B -MRE11A and Breast Cancer
19
CLU 8p21-p12 CLI, AAG4, APOJ, CLU1, CLU2, KUB1, SGP2, APO-J, SGP-2, SP-40, TRPM2, TRPM-2, NA1/NA2 -CLU and Breast Cancer
19
GSTA1 6p12.1 GST2, GTH1, GSTA1-1 -GSTA1 and Breast Cancer
19
M6PR 12p13 SMPR, MPR46, CD-MPR, MPR 46, MPR-46 -M6PR and Breast Cancer
19
POLL 10q23 BETAN, POLKAPPA -POLL and Breast Cancer
19
FGF1 5q31 AFGF, ECGF, FGFA, ECGFA, ECGFB, FGF-1, HBGF1, HBGF-1, GLIO703, ECGF-beta, FGF-alpha -FGF1 and Breast Cancer
19
NOS3 7q36 eNOS, ECNOS -NOS3 and Breast Cancer
19
EIF4EBP1 8p12 BP-1, 4EBP1, 4E-BP1, PHAS-I -EIF4EBP1 and Breast Cancer
19
CD9 12p13.3 MIC3, MRP-1, BTCC-1, DRAP-27, TSPAN29, TSPAN-29 -CD9 expression in Breast Cancer
19
DDIT3 12q13.1-q13.2 CHOP, CEBPZ, CHOP10, CHOP-10, GADD153 -DDIT3 and Breast Cancer
19
SCFV 14 -SCFV and Breast Cancer
18
APOE 19q13.2 AD2, LPG, APO-E, LDLCQ5 -APOE and Breast Cancer
18
PELP1 17p13.2 MNAR, P160 -PELP1 and Breast Cancer
18
NOTCH3 19p13.2-p13.1 IMF2, CASIL, CADASIL -NOTCH3 and Breast Cancer
18
OGG1 3p26.2 HMMH, MUTM, OGH1, HOGG1 -OGG1 and Breast Cancer
18
AKT3 1q44 MPPH, PKBG, MPPH2, PRKBG, STK-2, PKB-GAMMA, RAC-gamma, RAC-PK-gamma -AKT3 and Breast Cancer
18
ID2 2p25 GIG8, ID2A, ID2H, bHLHb26 -ID2 Expression in Breast Cancer
18
POU5F1 6p21.31 OCT3, OCT4, OTF3, OTF4, OTF-3, Oct-3, Oct-4 -POU5F1 and Breast Cancer
18
HIC1 17p13.3 hic-1, ZBTB29, ZNF901 -HIC1 and Breast Cancer
18
IGFBP1 7p12.3 AFBP, IBP1, PP12, IGF-BP25, hIGFBP-1 -IGFBP1 and Breast Cancer
18
S100A7 1q21 PSOR1, S100A7c -S100A7 and Breast Cancer
18
CTTN 11q13 EMS1 -CTTN and Breast Cancer
18
ERCC4 16p13.12 XPF, RAD1, FANCQ, ERCC11 -ERCC4 and Breast Cancer
17
MYBL2 20q13.1 BMYB, B-MYB -MYBL2 and Breast Cancer
17
CSK 15q24.1 -CSK and Breast Cancer
17
CDC25C 5q31 CDC25, PPP1R60 -CDC25C and Breast Cancer
17
XRCC4 5q14.2 -XRCC4 and Breast Cancer
17
ETS2 21q22.2 ETS2IT1 -ETS2 and Breast Cancer
17
ELK1 Xp11.2 -ELK1 and Breast Cancer
17
TCF7L2 10q25.3 TCF4, TCF-4 -TCF7L2 and Breast Cancer
17
MECP2 Xq28 RS, RTS, RTT, PPMX, MRX16, MRX79, MRXSL, AUTSX3, MRXS13 -MECP2 and Breast Cancer
17
CTLA4 2q33 CD, GSE, GRD4, ALPS5, CD152, CTLA-4, IDDM12, CELIAC3 -CTLA4 and Breast Cancer
17
MMP14 14q11.2 MMP-14, MMP-X1, MT-MMP, MT1MMP, MTMMP1, WNCHRS, MT1-MMP, MT-MMP 1 -MMP14 and Breast Cancer
17
CDH13 16q23.3 CDHH, P105 -CDH13 and Breast Cancer
17
ITGB4 17q25 CD104 -ITGB4 and Breast Cancer
17
MMP13 11q22.3 CLG3, MANDP1, MMP-13 -MMP13 and Breast Cancer
17
MTRR 5p15.31 MSR, cblE -MTRR and Breast Cancer
17
HFE 6p21.3 HH, HFE1, HLA-H, MVCD7, TFQTL2 -HFE and Breast Cancer
17
GPX1 3p21.3 GPXD, GSHPX1 -GPX1 and Breast Cancer
16
YBX1 1p34 YB1, BP-8, CSDB, DBPB, YB-1, CSDA2, NSEP1, NSEP-1, MDR-NF1 -YBX1 and Breast Cancer
16
AGR2 7p21.3 AG2, GOB-4, HAG-2, XAG-2, PDIA17, HEL-S-116 -AGR2 and Breast Cancer
16
HDAC3 5q31 HD3, RPD3, RPD3-2 -HDAC3 and Breast Cancer
16
CREB1 2q34 CREB -CREB1 and Breast Cancer
16
STAT5B 17q11.2 STAT5 -STAT5B and Breast Cancer
16
CYP2C8 10q23.33 CPC8, CYPIIC8, MP-12/MP-20 -CYP2C8 and Breast Cancer
16
PITX2 4q25 RS, RGS, ARP1, Brx1, IDG2, IGDS, IHG2, PTX2, RIEG, IGDS2, IRID2, Otlx2, RIEG1 -PITX2 and Breast Cancer
16
DNMT3A 2p23 TBRS, DNMT3A2, M.HsaIIIA -DNMT3A and Breast Cancer
16
SATB1 3p23 -SATB1 and Breast Cancer
16
TLR4 9q33.1 TOLL, CD284, TLR-4, ARMD10 -TLR4 and Breast Cancer
16
CREBBP 16p13.3 CBP, RSTS, KAT3A -CREBBP and Breast Cancer
16
GREB1 2p25.1 -GREB1 and Breast Cancer
16
RRM2 2p25-p24 R2, RR2, RR2M -RRM2 and Breast Cancer
15
APOD 3q29 -APOD and Breast Cancer
15
PTTG1 5q35.1 EAP1, PTTG, HPTTG, TUTR1 -PTTG1 and Breast Cancer
15
WISP2 20q13.12 CCN5, CT58, CTGF-L -WISP2 and Breast Cancer
15
CTNNA1 5q31.2 CAP102 -CTNNA1 and Breast Cancer
15
CLDN1 3q28-q29 CLD1, SEMP1, ILVASC -CLDN1 and Breast Cancer
15
CCND3 6p21 -CCND3 and Breast Cancer
15
CXCL2 4q21 GRO2, GROb, MIP2, MIP2A, SCYB2, MGSA-b, MIP-2a, CINC-2a -CXCL2 and Breast Cancer
15
RELB 19q13.32 IREL, I-REL, REL-B -RELB and Breast Cancer
15
TIAM1 21q22.11 -TIAM1 and Breast Cancer
15
RARB 3p24.2 HAP, RRB2, NR1B2, MCOPS12 -RARB and Breast Cancer
15
NEK2 1q32.3 NLK1, RP67, NEK2A, HsPK21, PPP1R111 -NEK2 and Breast Cancer
15
MARCO 2q14.2 SCARA2 -MARCO and Breast Cancer
15
CCL5 17q12 SISd, eoCP, SCYA5, RANTES, TCP228, D17S136E, SIS-delta -CCL5 and Breast Cancer
15
PIK3CB 3q22.3 PI3K, PIK3C1, P110BETA, PI3KBETA -PIK3CB and Breast Cancer
15
BBC3 19q13.3-q13.4 JFY1, PUMA, JFY-1 -BBC3 and Breast Cancer
15
IRS2 13q34 IRS-2 -IRS2 and Breast Cancer
14
ZNF350 19q13.41 ZFQR, ZBRK1 -ZNF350 and Breast Cancer
14
CYP27B1 12q14.1 VDR, CP2B, CYP1, PDDR, VDD1, VDDR, VDDRI, CYP27B, P450c1, CYP1alpha -CYP27B1 and Breast Cancer
14
MIRLET7B 22q13.31 LET7B, let-7b, MIRNLET7B, hsa-let-7b -MicroRNA let-7b and Breast Cancer
14
RAD51B 14q23-q24.2 REC2, R51H2, RAD51L1 -RAD51B and Breast Cancer
14
FOXC1 6p25 ARA, IGDA, IHG1, FKHL7, IRID1, RIEG3, FREAC3, FREAC-3 -FOXC1 and Breast Cancer
14
TGFB2 1q41 LDS4, TGF-beta2 -TGFB2 and Breast Cancer
14
NCOR2 12q24 SMRT, TRAC, CTG26, SMRTE, TRAC1, N-CoR2, TNRC14, TRAC-1, SMAP270, SMRTE-tau -NCOR2 and Breast Cancer
14
NOTCH4 6p21.3 INT3 -NOTCH4 and Breast Cancer
14
SRD5A2 2p23 -SRD5A2 and Breast Cancer
14
TNFRSF10A 8p21 DR4, APO2, CD261, TRAILR1, TRAILR-1 -TNFRSF10A and Breast Cancer
14
IGFBP5 2q35 IBP5 -IGFBP5 and Breast Cancer
14
PDK1 2q31.1 -PDK1 and Breast Cancer
14
DLX4 17q21.33 BP1, DLX7, DLX8, DLX9 -DLX4 and Breast Cancer
14
KLK10 19q13 NES1, PRSSL1 -KLK10 and Breast Cancer
14
E2F3 6p22 E2F-3 -E2F3 and Breast Cancer
14
CYR61 1p22.3 CCN1, GIG1, IGFBP10 -CYR61 and Breast Cancer
14
PEBP1 12q24.23 PBP, HCNP, PEBP, RKIP, HCNPpp, PEBP-1, HEL-210, HEL-S-34 -PEBP1 and Breast Cancer
14
SPDEF 6p21.3 PDEF, bA375E1.3 -SPDEF and Breast Cancer
14
VIP 6q25 PHM27 -VIP and Breast Cancer
14
IL11 19q13.3-q13.4 AGIF, IL-11 -IL11 and Breast Cancer
14
JAG1 20p12.1-p11.23 AGS, AHD, AWS, HJ1, CD339, JAGL1 -JAG1 and Breast Cancer
14
SSTR2 17q24 -SSTR2 and Breast Cancer
14
ARNT 1q21 HIF1B, TANGO, bHLHe2, HIF1BETA, HIF-1beta, HIF1-beta, HIF-1-beta -ARNT and Breast Cancer
14
WNT3 17q21 INT4, TETAMS -WNT3 and Breast Cancer
14
NOS2 17q11.2 NOS, INOS, NOS2A, HEP-NOS -NOS2 and Breast Cancer
14
BNIP3 10q26.3 NIP3 -BNIP3 and Breast Cancer
14
ACTB 7p22 BRWS1, PS1TP5BP1 -ACTB and Breast Cancer
14
FES 15q26.1 FPS -FES and Breast Cancer
14
DLC1 8p22 HP, ARHGAP7, STARD12, p122-RhoGAP -Breast Cancer and DLC1
14
MBD2 18q21 DMTase, NY-CO-41 -MBD2 and Breast Cancer
14
REL 2p13-p12 C-Rel -REL and Breast Cancer
14
RHOB 2p24 ARH6, ARHB, RHOH6, MST081, MSTP081 -RHOB and Breast Cancer
13
WISP3 6q21 PPD, CCN6, LIBC, PPAC -WISP3 and Breast Cancer
13
HOXD10 2q31.1 HOX4, HOX4D, HOX4E, Hox-4.4 -HOXD10 and Breast Cancer
13
IGFBP4 17q21.2 BP-4, IBP4, IGFBP-4, HT29-IGFBP -IGFBP4 and Breast Cancer
13
MOS 8q11 MSV -MOS and Breast Cancer
13
GADD45A 1p31.2 DDIT1, GADD45 -GADD45A and Breast Cancer
13
VIM 10p13 HEL113, CTRCT30 -VIM and Breast Cancer
13
PARK2 6q25.2-q27 PDJ, PRKN, AR-JP, LPRS2 -PARK2 and Breast Cancer
13
RAD51D 17q11 TRAD, R51H3, BROVCA4, RAD51L3 -RAD51D and Breast Cancer
13
MAD2L1 4q27 MAD2, HSMAD2 -MAD2L1 and Breast Cancer
13
UBE2C 20q13.12 UBCH10, dJ447F3.2 -UBE2C and Breast Cancer
13
FYN 6q21 SLK, SYN, p59-FYN -FYN and Breast Cancer
13
HSPB1 7q11.23 CMT2F, HMN2B, HSP27, HSP28, Hsp25, SRP27, HS.76067, HEL-S-102 -HSPB1 and Breast Cancer
13
PRKDC 8q11 HYRC, p350, DNAPK, DNPK1, HYRC1, IMD26, XRCC7, DNA-PKcs -PRKDC and Breast Cancer
13
CCR5 3p21.31 CKR5, CCR-5, CD195, CKR-5, CCCKR5, CMKBR5, IDDM22, CC-CKR-5 -CCR5 and Breast Cancer
12
SIPA1 11q13 SPA1 -SIPA1 and Breast Cancer
12
CAST 5q15 BS-17, PLACK -CAST and Breast Cancer
12
ITGB3 17q21.32 GT, CD61, GP3A, BDPLT2, GPIIIa, BDPLT16 -ITGB3 and Breast Cancer
12
FASN 17q25 FAS, OA-519, SDR27X1 -FASN and Breast Cancer
12
ADAM12 10q26 MCMP, MLTN, CAR10, MLTNA, MCMPMltna, ADAM12-OT1 -ADAM12 and Breast Cancer
12
CARM1 19p13.2 PRMT4 -CARM1 and Breast Cancer
12
RAD21 8q24 HR21, MCD1, NXP1, SCC1, CDLS4, hHR21, HRAD21 -RAD21 and Breast Cancer
12
MAP2K4 17p12 JNKK, MEK4, MKK4, SEK1, SKK1, JNKK1, SERK1, MAPKK4, PRKMK4, SAPKK1, SAPKK-1 -MAP2K4 and Breast Cancer
12
MSN Xq11.1 HEL70 -MSN and Breast Cancer
12
SNAI2 8q11 SLUG, WS2D, SLUGH1, SNAIL2 -SNAI2 and Breast Cancer
12
NFKB1 4q24 p50, KBF1, p105, EBP-1, NF-kB1, NFKB-p50, NFkappaB, NF-kappaB, NFKB-p105, NF-kappa-B -NFKB1 and Breast Cancer
12
AMPH 7p14-p13 AMPH1 Overexpression
-AMPH Expression in Stiff-Person Syndrome associated Breast Cancer
12
TOPBP1 3q22.1 TOP2BP1 -TOPBP1 and Breast Cancer
12
CD68 17p13 GP110, LAMP4, SCARD1 -CD68 and Breast Cancer
12
BMP6 6p24-p23 VGR, VGR1 -BMP6 and Breast Cancer
12
LMO4 1p22.3 -LMO4 and Breast Cancer
12
SIX1 14q23.1 BOS3, TIP39, DFNA23 -SIX1 and Breast Cancer
12
TACSTD2 1p32 EGP1, GP50, M1S1, EGP-1, TROP2, GA7331, GA733-1 -TACSTD2 and Breast Cancer
12
CD74 5q32 II, DHLAG, HLADG, Ia-GAMMA -CD74 and Breast Cancer
12
KDR 4q11-q12 FLK1, CD309, VEGFR, VEGFR2 -KDR and Breast Cancer
12
MED1 17q12 PBP, CRSP1, RB18A, TRIP2, PPARBP, CRSP200, DRIP205, DRIP230, PPARGBP, TRAP220 -MED1 and Breast Cancer
12
SNAI1 20q13.2 SNA, SNAH, SNAIL, SLUGH2, SNAIL1, dJ710H13.1 -SNAI1 and Breast Cancer
12
TPM3 1q21.2 TM3, TM5, TRK, CFTD, NEM1, TM-5, TM30, CAPM1, TM30nm, TPMsk3, hscp30, HEL-189, HEL-S-82p, OK/SW-cl.5 -TPM3 and Breast Cancer
12
RFC1 4p14-p13 A1, RFC, PO-GA, RECC1, MHCBFB, RFC140 -RFC1 and Breast Cancer
12
PWAR1 15q11.2 PAR1, PAR-1, D15S227E -PAR1 and Breast Cancer
12
SHC1 1q21 SHC, SHCA -SHC1 and Breast Cancer
12
EIF3E 8q22-q23 INT6, EIF3S6, EIF3-P48, eIF3-p46 -EIF3E and Breast Cancer
11
HLA-G 6p21.3 MHC-G -HLA-G and Breast Cancer
11
BAP1 3p21.1 UCHL2, hucep-6, HUCEP-13 -BAP1 and Breast Cancer
11
PIGS 17p13.2 -PIGS and Breast Cancer
11
SERPINB5 18q21.33 PI5, maspin -SERPINB5 and Breast Cancer
11
BTG2 1q32 PC3, TIS21 -BTG2 and Breast Cancer
11
ALCAM 3q13.1 MEMD, CD166 -ALCAM and Breast Cancer
11
HOXB7 17q21.3 HOX2, HOX2C, HHO.C1, Hox-2.3 -HOXB7 and Breast Cancer
11
AKR1C3 10p15-p14 DD3, DDX, PGFS, HAKRB, HAKRe, HA1753, HSD17B5, hluPGFS -AKR1C3 and Breast Cancer
11
TBX2 17q23.2 -TBX2 and Breast Cancer
11
RBBP8 18q11.2 RIM, COM1, CTIP, JWDS, SAE2, SCKL2 -RBBP8 and Breast Cancer
11
CCNE2 8q22.1 CYCE2 -CCNE2 and Breast Cancer
11
PYCARD 16p11.2 ASC, TMS, TMS1, CARD5, TMS-1 -PYCARD and Breast Cancer
11
KRT19 17q21.2 K19, CK19, K1CS -KRT19 and Breast Cancer
11
RPS6KB1 17q23.1 S6K, PS6K, S6K1, STK14A, p70-S6K, p70 S6KA, p70-alpha, S6K-beta-1, p70(S6K)-alpha -RPS6KB1 and Breast Cancer
11
NFIB 9p24.1 CTF, NF1-B, NFI-B, NFIB2, NFIB3, NF-I/B, NFI-RED, HMGIC/NFIB -NFIB and Breast Cancer
11
LCN2 9q34 24p3, MSFI, NGAL -LCN2 and Breast Cancer
11
HDAC2 6q21 HD2, RPD3, YAF1 -HDAC2 and Breast Cancer
11
MAPK8 10q11.22 JNK, JNK1, PRKM8, SAPK1, JNK-46, JNK1A2, SAPK1c, JNK21B1/2 -MAPK8 and Breast Cancer
11
HDAC6 Xp11.23 HD6, JM21, CPBHM, PPP1R90 -HDAC6 and Breast Cancer
11
ANXA5 4q27 PP4, ANX5, ENX2, RPRGL3, HEL-S-7 -ANXA5 and Breast Cancer
11
TRPS1 8q24.12 GC79, LGCR -TRPS1 and Breast Cancer
11
GDF15 19p13.11 PDF, MIC1, PLAB, MIC-1, NAG-1, PTGFB, GDF-15 -GDF15 and Breast Cancer
11
WNT3A 1q42 -WNT3A and Breast Cancer
10
HSF1 8q24.3 HSTF1 -HSF1 and Breast Cancer
10
ATG5 6q21 ASP, APG5, APG5L, hAPG5, APG5-LIKE -ATG5 and Breast Cancer
10
ST3 11q13-q23 CCTS, TSHL -ST3 and Breast Cancer
10
BIK 22q13.31 BP4, NBK, BIP1 -BIK and Breast Cancer
10
RAF1 3p25 NS5, CRAF, Raf-1, c-Raf, CMD1NN -RAF1 and Breast Cancer
10
CUL4A 13q34 -CUL4A and Breast Cancer
10
SDC1 2p24.1 SDC, CD138, SYND1, syndecan -SDC1 and Breast Cancer
10
TBX3 12q24.21 UMS, XHL, TBX3-ISO -TBX3 and Breast Cancer
10
DHFR 5q14.1 DYR, DHFRP1 -DHFR and Breast Cancer
10
GHRH 20q11.2 GRF, INN, GHRF -GHRH and Breast Cancer
10
IRF1 5q31.1 MAR, IRF-1 -IRF1 and Breast Cancer
10
BLM 15q26.1 BS, RECQ2, RECQL2, RECQL3 -BLM and Breast Cancer
10
FEN1 11q12 MF1, RAD2, FEN-1 -FEN1 and Breast Cancer
10
CCR7 17q12-q21.2 BLR2, EBI1, CCR-7, CD197, CDw197, CMKBR7, CC-CKR-7 -CCR7 and Breast Cancer
10
ANXA1 9q21.13 ANX1, LPC1 -ANXA1 and Breast Cancer
10
BMP4 14q22-q23 ZYME, BMP2B, OFC11, BMP2B1, MCOPS6 -BMP4 and Breast Cancer
10
HMGB1 13q12 HMG1, HMG3, SBP-1 -HMGB1 and Breast Cancer
10
E2F2 1p36 E2F-2 -E2F2 and Breast Cancer
10
WEE1 11p15.4 WEE1A, WEE1hu -WEE1 and Breast Cancer
10
STMN1 1p36.11 Lag, SMN, OP18, PP17, PP19, PR22, LAP18, C1orf215 -STMN1 and Breast Cancer
10
ADH1C 4q23 ADH3 -ADH1C and Breast Cancer
10
CDC20 1p34.1 CDC20A, p55CDC, bA276H19.3 -CDC20 and Breast Cancer
10
BCAR3 1p22.1 NSP2, SH2D3B -BCAR3 and Breast Cancer
10
TRAF2 9q34 TRAP, TRAP3, MGC:45012 -TRAF2 and Breast Cancer
10
ATF4 22q13.1 CREB2, TXREB, CREB-2, TAXREB67 -ATF4 and Breast Cancer
10
SOD1 21q22.11 ALS, SOD, ALS1, IPOA, hSod1, HEL-S-44, homodimer -SOD1 and Breast Cancer
10
CIC 19q13.2 -CIC and Breast Cancer
10
NME2 17q21.3 PUF, NDKB, NDPKB, NM23B, NDPK-B, NM23-H2 -NME2 and Breast Cancer
10
KLF5 13q22.1 CKLF, IKLF, BTEB2 -KLF5 and Breast Cancer
10
CDC25B 20p13 -CDC25B and Breast Cancer
10
IBSP 4q21.1 BSP, BNSP, SP-II, BSP-II -IBSP and Breast Cancer
10
CKAP4 12q23.3 p63, CLIMP-63, ERGIC-63 -CKAP4 and Breast Cancer
10
ADIPOR1 1q32.1 CGI45, PAQR1, ACDCR1, CGI-45, TESBP1A -ADIPOR1 and Breast Cancer
10
HOXA5 7p15.2 HOX1, HOX1C, HOX1.3 -HOXA5 and Breast Cancer
10
ELF3 1q32.2 ERT, ESX, EPR-1, ESE-1 -ELF3 and Breast Cancer
10
MARS 12q13.3 MRS, METRS, MTRNS, SPG70 -MARS and Breast Cancer
10
PLAU 10q22.2 ATF, QPD, UPA, URK, u-PA, BDPLT5 -PLAU and Breast Cancer
9
IL17A 6p12 IL17, CTLA8, IL-17, IL-17A -IL17A and Breast Cancer
9
WIF1 12q14.3 WIF-1 -WIF1 and Breast Cancer
9
PSEN2 1q42.13 AD4, PS2, AD3L, STM2, CMD1V -PSEN2 and Breast Cancer
9
CEBPD 8p11.2-p11.1 CELF, CRP3, C/EBP-delta, NF-IL6-beta -CEBPD and Breast Cancer
9
FURIN 15q26.1 FUR, PACE, SPC1, PCSK3 -FURIN and Breast Cancer
9
PMAIP1 18q21.32 APR, NOXA -PMAIP1 and Breast Cancer
9
CSF1 1p13.3 MCSF, CSF-1 -CSF1 and Breast Cancer
9
PER2 2q37.3 FASPS, FASPS1 -PER2 and Breast Cancer
9
NFKB2 10q24 p52, p100, H2TF1, LYT10, CVID10, LYT-10, NF-kB2 -NFKB2 and Breast Cancer
9
FGF8 10q24 HH6, AIGF, KAL6, FGF-8, HBGF-8 -FGF8 and Breast Cancer
9
RARS 5q35.1 HLD9, ArgRS, DALRD1 -RARS and Breast Cancer
9
WARS 14q32.31 IFI53, IFP53, GAMMA-2 -WARS and Breast Cancer
9
CCNB2 15q22.2 HsT17299 -CCNB2 and Breast Cancer
9
RECK 9p13.3 ST15 -RECK and Breast Cancer
9
UGT2B7 4q13 UGT2B9, UDPGTH2, UDPGT2B7, UDPGT 2B9 -UGT2B7 and Breast Cancer
9
RHOBTB2 8p21.3 DBC2 -RHOBTB2 and Breast Cancer
9
ABCC2 10q24 DJS, MRP2, cMRP, ABC30, CMOAT -ABCC2 and Breast Cancer
9
LIF 22q12.2 CDF, DIA, HILDA, MLPLI -LIF and Breast Cancer
9
ARID1A 1p35.3 ELD, B120, OSA1, P270, hELD, BM029, MRD14, hOSA1, BAF250, C1orf4, BAF250a, SMARCF1 -ARID1A and Breast Cancer
9
AGO2 8q24 Q10, EIF2C2 -EIF2C2 and Breast Cancer
9
IL1B 2q14 IL-1, IL1F2, IL1-BETA -IL1B and Breast Cancer
9
TGFB3 14q24 ARVD, RNHF, ARVD1, TGF-beta3 -TGFB3 and Breast Cancer
9
CRP 1q23.2 PTX1 -CRP and Breast Cancer
9
HAS2 8q24.12 -HAS2 and Breast Cancer
9
COL1A1 17q21.33 OI4 -COL1A1 and Breast Cancer
9
PTPN13 4q21.3 PNP1, FAP-1, PTP1E, PTPL1, PTPLE, PTP-BL, hPTP1E, PTP-BAS -PTPN13 and Breast Cancer
9
BMP2 20p12 BDA2, BMP2A -BMP2 and Breast Cancer
9
SUZ12 17q11.2 CHET9, JJAZ1 -SUZ12 and Breast Cancer
9
RAB25 1q22 CATX-8, RAB11C -RAB25 and Breast Cancer
9
YES1 18p11.31-p11.21 Yes, c-yes, HsT441, P61-YES -Proto-Oncogene Proteins c-yes and Breast Cancer
9
IGFBP2 2q35 IBP2, IGF-BP53 -IGFBP2 and Breast Cancer
9
TUBB3 16q24.3 CDCBM, FEOM3, TUBB4, CDCBM1, CFEOM3, beta-4, CFEOM3A -TUBB3 and Breast Cancer
9
ANGPT2 8p23.1 ANG2, AGPT2 -ANGPT2 and Breast Cancer
9
MUTYH 1p34.1 MYH -MUTYH and Breast Cancer
9
TPD52 8q21.13 D52, N8L, PC-1, PrLZ, hD52 -TPD52 and Breast Cancer
9
TP73 1p36.3 P73 -TP73 and Breast Cancer
9
MALL 2q13 BENE -MALL and Breast Cancer
9
COPS5 8q13.1 CSN5, JAB1, SGN5, MOV-34 -COPS5 and Breast Cancer
9
CXCL10 4q21 C7, IFI10, INP10, IP-10, crg-2, mob-1, SCYB10, gIP-10 -CXCL10 and Breast Cancer
9
TCF3 19p13.3 E2A, E47, ITF1, VDIR, TCF-3, bHLHb21 -TCF3 and Breast Cancer
9
AKR1C2 10p15-p14 DD, DD2, TDD, BABP, DD-2, DDH2, HBAB, HAKRD, MCDR2, SRXY8, DD/BABP, AKR1C-pseudo -AKR1C2 and Breast Cancer
9
IL18 11q22.2-q22.3 IGIF, IL-18, IL-1g, IL1F4 -IL18 and Breast Cancer
9
TLR9 3p21.3 CD289 -TLR9 and Breast Cancer
9
GPC3 Xq26.1 SGB, DGSX, MXR7, SDYS, SGBS, OCI-5, SGBS1, GTR2-2 -GPC3 and Breast Cancer
9
RPA1 17p13.3 HSSB, RF-A, RP-A, REPA1, RPA70, MST075 -RPA1 and Breast Cancer
8
B2M 15q21.1 -B2M and Breast Cancer
8
EFNB2 13q33 HTKL, EPLG5, Htk-L, LERK5 -EFNB2 expression in Breast Cancer
8
DKK3 11p15.2 RIG, REIC -DKK3 and Breast Cancer
8
RICTOR 5p13.1 PIA, AVO3, hAVO3 -RICTOR and Breast Cancer
8
SUV39H1 Xp11.23 MG44, KMT1A, SUV39H, H3-K9-HMTase 1 -SUV39H1 and Breast Cancer
8
HOXA1 7p15.3 BSAS, HOX1, HOX1F -HOXA1 and Breast Cancer
8
TFPI 2q32 EPI, TFI, LACI, TFPI1 -TFPI and Breast Cancer
8
BMP7 20q13 OP-1 -BMP7 and Breast Cancer
8
PRINS 10p12.1 NCRNA00074 -PRINS and Breast Cancer
8
POSTN 13q13.3 PN, OSF2, OSF-2, PDLPOSTN, periostin -POSTN and Breast Cancer
8
WNT10B 12q13 SHFM6, WNT-12 -WNT10B and Breast Cancer
8
BUB3 10q26 BUB3L, hBUB3 -BUB3 and Breast Cancer
8
S100A8 1q21 P8, MIF, NIF, CAGA, CFAG, CGLA, L1Ag, MRP8, CP-10, MA387, 60B8AG -S100A8 and Breast Cancer
8
DUSP1 5q34 HVH1, MKP1, CL100, MKP-1, PTPN10 -DUSP1 and Breast Cancer
8
ADAM9 8p11.22 MCMP, MDC9, CORD9, Mltng -ADAM9 and Breast Cancer
8
CASP10 2q33-q34 MCH4, ALPS2, FLICE2 -CASP10 and Breast Cancer
8
ATG7 3p25.3 GSA7, APG7L, APG7-LIKE -ATG7 and Breast Cancer
8
BNIP3L 8p21 NIX, BNIP3a -BNIP3L and Breast Cancer
8
CDC6 17q21.3 CDC18L, HsCDC6, HsCDC18 -CDC6 and Breast Cancer
8
KL 13q12 -KL and Breast Cancer
8
EPHB6 7q33-q35 HEP -EPHB6 and Breast Cancer
8
FCGR3A 1q23 CD16, FCG3, CD16A, FCGR3, IGFR3, IMD20, FCR-10, FCRIII, FCGRIII, FCRIIIA -FCGR3A and Breast Cancer
8
MSX2 5q35.2 FPP, MSH, PFM, CRS2, HOX8, PFM1 -MSX2 and Breast Cancer
8
TLR3 4q35 CD283, IIAE2 -TLR3 and Breast Cancer
8
KLK14 19q13.3-q13.4 KLK-L6 -KLK14 and Breast Cancer
8
ERCC5 13q33 XPG, UVDR, XPGC, COFS3, ERCM2, ERCC5-201 -ERCC5 and Breast Cancer
8
L1CAM Xq28 S10, HSAS, MASA, MIC5, SPG1, CAML1, CD171, HSAS1, N-CAML1, NCAM-L1, N-CAM-L1 -L1CAM and Breast Cancer
8
HBEGF 5q23 DTR, DTS, DTSF, HEGFL -HBEGF and Breast Cancer
8
NDRG1 8q24.3 GC4, RTP, DRG1, NDR1, NMSL, TDD5, CAP43, CMT4D, DRG-1, HMSNL, RIT42, TARG1, PROXY1 -NDRG1 and Breast Cancer
8
TEP1 14q11.2 TP1, TLP1, p240, TROVE1, VAULT2 -TEP1 and Breast Cancer
8
KDM1A 1p36.12 AOF2, KDM1, LSD1, BHC110 -KDM1A and Breast Cancer
8
KPNA2 17q24.2 QIP2, RCH1, IPOA1, SRP1alpha -KPNA2 and Breast Cancer
8
ADRB2 5q31-q32 BAR, B2AR, ADRBR, ADRB2R, BETA2AR -ADRB2 and Breast Cancer
8
IL17C 16q24 CX2, IL-17C -IL17C and Breast Cancer
8
TRA 14q11.2 IMD7, TCRA, TCRD, TRA@, TRAC -TRA and Breast Cancer
8
NQO2 6p25.2 QR2, DHQV, DIA6, NMOR2 -NQO2 and Breast Cancer
8
SOX11 2p25 MRD27 -SOX11 and Breast Cancer
8
SOCS3 17q25.3 CIS3, SSI3, ATOD4, Cish3, SSI-3, SOCS-3 -SOCS3 and Breast Cancer
8
CUL1 7q36.1 -CUL1 and Breast Cancer
8
BRD4 19p13.1 CAP, MCAP, HUNK1, HUNKI -BRD4 and Breast Cancer
8
KLK6 19q13.3 hK6, Bssp, Klk7, SP59, PRSS9, PRSS18 -KLK6 and Breast Cancer
8
BIN1 2q14 AMPH2, AMPHL, SH3P9 -BIN1 and Breast Cancer
8
ATF2 2q32 HB16, CREB2, TREB7, CREB-2, CRE-BP1 -ATF2 and Breast Cancer
8
SUMO1 2q33 DAP1, GMP1, PIC1, SMT3, UBL1, OFC10, SENP2, SMT3C, SMT3H3 -SUMO1 and Breast Cancer
8
CBFA2T3 16q24 ETO2, MTG16, MTGR2, ZMYND4 -CBFA2T3 and Breast Cancer
8
LATS1 6q25.1 wts, WARTS -LATS1 and Breast Cancer
8
AXL 19q13.1 ARK, UFO, JTK11, Tyro7 -AXL and Breast Cancer
8
CXCR2 2q35 CD182, IL8R2, IL8RA, IL8RB, CMKAR2, CDw128b -CXCR2 and Breast Cancer
8
MDC1 6p21.3 NFBD1 -MDC1 and Breast Cancer
8
TES 7q31.2 TESS, TESS-2 -TES and Breast Cancer
8
CDH3 16q22.1 CDHP, HJMD, PCAD -CDH3 and Breast Cancer
8
KDM5B 1q32.1 CT31, PLU1, PUT1, PLU-1, JARID1B, PPP1R98, RBBP2H1A -KDM5B and Breast Cancer
8
DDB2 11p12-p11 DDBB, UV-DDB2 -DDB2 and Breast Cancer
8
CDH2 18q11.2 CDHN, NCAD, CD325, CDw325 -CDH2 and Breast Cancer
8
LIG4 13q33-q34 LIG4S -LIG4 and Breast Cancer
8
NR5A2 1q32.1 B1F, CPF, FTF, B1F2, LRH1, LRH-1, FTZ-F1, hB1F-2, FTZ-F1beta -NR5A2 and Breast Cancer
8
SOX4 6p22.3 EVI16 -SOX4 and Breast Cancer
8
INSR 19p13.3-p13.2 HHF5, CD220 -INSR and Breast Cancer
8
SKP1 5q31 OCP2, p19A, EMC19, SKP1A, OCP-II, TCEB1L -SKP1 and Breast Cancer
8
DDX5 17q21 p68, HLR1, G17P1, HUMP68 -DDX5 and Breast Cancer
8
POT1 7q31.33 CMM10, HPOT1 -POT1 and Breast Cancer
8
CLDN4 7q11.23 CPER, CPE-R, CPETR, CPETR1, WBSCR8, hCPE-R -CLDN4 and Breast Cancer
8
CASP1 11q23 ICE, P45, IL1BC -CASP1 and Breast Cancer
8
PDPK1 16p13.3 PDK1, PDPK2, PDPK2P, PRO0461 -PDPK1 and Breast Cancer
8
BUB1B 15q15 MVA1, SSK1, BUBR1, Bub1A, MAD3L, hBUBR1, BUB1beta -BUB1B and Breast Cancer
8
XIST Xq13.2 SXI1, swd66, DXS1089, DXS399E, LINC00001, NCRNA00001 -XIST and Breast Cancer
8
KEAP1 19p13.2 INrf2, KLHL19 -KEAP1 and Breast Cancer
8
GSTM3 1p13.3 GST5, GSTB, GTM3, GSTM3-3 -GSTM3 and Breast Cancer
7
S100P 4p16 MIG9 -S100P and Breast Cancer
7
IKBKE 1q32.1 IKKE, IKKI, IKK-E, IKK-i -IKBKE and Breast Cancer
7
FOXC2 16q24.1 LD, MFH1, MFH-1, FKHL14 -FOXC2 and Breast Cancer
7
ALDH3A1 17p11.2 ALDH3, ALDHIII -ALDH3A1 and Breast Cancer
7
GATA4 8p23.1-p22 TOF, ASD2, VSD1, TACHD -GATA4 and Breast Cancer
7
PAEP 9q34 GD, GdA, GdF, GdS, PEP, PAEG, PP14 -PAEP and Breast Cancer
7
HMMR 5q34 CD168, IHABP, RHAMM -HMMR and Breast Cancer
7
FGF10 5p13-p12 -FGF10 and Breast Cancer
7
TJP1 15q13 ZO-1 -TJP1 and Breast Cancer
7
ATF3 1q32.3 -ATF3 and Breast Cancer
7
BMPR2 2q33-q34 BMR2, PPH1, BMPR3, BRK-3, POVD1, T-ALK, BMPR-II -BMPR2 and Breast Cancer
7
PON1 7q21.3 ESA, PON, MVCD5 -PON1 and Breast Cancer
7
NCOA2 8q13.3 SRC2, TIF2, GRIP1, KAT13C, NCoA-2, bHLHe75 -NCOA2 and Breast Cancer
7
XBP1 22q12.1 XBP2, TREB5, XBP-1, TREB-5 -XBP1 and Breast Cancer
7
MAML1 5q35 Mam1, Mam-1 -MAML1 and Breast Cancer
7
GAB2 11q14.1 -GAB2 and Breast Cancer
7
PIK3R1 5q13.1 p85, AGM7, GRB1, IMD36, p85-ALPHA -PIK3R1 and Breast Cancer
7
IQGAP1 15q26.1 SAR1, p195, HUMORFA01 -IQGAP1 and Breast Cancer
7
KRT18 12q13 K18, CYK18 -KRT18 and Breast Cancer
7
CTSD 11p15.5 CPSD, CLN10, HEL-S-130P -CTSD and Breast Cancer
7
ZFP36 19q13.1 TTP, G0S24, GOS24, TIS11, NUP475, zfp-36, RNF162A -ZFP36 and Breast Cancer
7
S100A9 1q21 MIF, NIF, P14, CAGB, CFAG, CGLB, L1AG, LIAG, MRP14, 60B8AG, MAC387 -S100A9 and Breast Cancer
7
PTPRQ 12q21.2 DFNB84, DFNB84A, PTPGMC1, R-PTP-Q -PTPRQ and Breast Cancer
7
SREBF1 17p11.2 SREBP1, bHLHd1, SREBP-1c -SREBF1 and Breast Cancer
7
PTPRH 19q13.4 SAP1, R-PTP-H -PTPRH and Breast Cancer
7
NR4A1 12q13 HMR, N10, TR3, NP10, GFRP1, NAK-1, NGFIB, NUR77 -NR4A1 and Breast Cancer
7
MIR127 14q32.2 MIRN127, miRNA127 -MicroRNA miR-127 and Breast Cancer
7
ADIPOQ 3q27 ACDC, ADPN, APM1, APM-1, GBP28, ACRP30, ADIPQTL1 -ADIPOQ and Breast Cancer
7
IL1A 2q14 IL1, IL-1A, IL1F1, IL1-ALPHA -IL1A and Breast Cancer
7
PTPRT 20q12-q13 RPTPrho -PTPRT and Breast Cancer
7
ADIPOR2 12p13.31 PAQR2, ACDCR2 -ADIPOR2 and Breast Cancer
7
NEDD4 15q RPF1, NEDD4-1 -NEDD4 and Breast Cancer
7
STAT6 12q13 STAT6B, STAT6C, D12S1644, IL-4-STAT -STAT6 and Breast Cancer
7
TERF2 16q22.1 TRF2, TRBF2 -TERF2 and Breast Cancer
7
IL13 5q31 P600, IL-13 -IL13 and Breast Cancer
7
HDAC4 2q37.3 HD4, AHO3, BDMR, HDACA, HA6116, HDAC-4, HDAC-A -HDAC4 and Breast Cancer
7
EPOR 19p13.3-p13.2 EPO-R -EPOR and Breast Cancer
7
AKR1C1 10p15-p14 C9, DD1, DDH, DDH1, H-37, HBAB, MBAB, HAKRC, DD1/DD2, 2-ALPHA-HSD, 20-ALPHA-HSD -AKR1C1 and Breast Cancer
7
NEFL 8p21 NFL, NF-L, NF68, CMT1F, CMT2E, PPP1R110 -NEFL and Breast Cancer
7
MICA 6p21.33 MIC-A, PERB11.1 -MICA and Breast Cancer
7
ADAM17 2p25 CSVP, TACE, NISBD, ADAM18, CD156B, NISBD1 -ADAM17 and Breast Cancer
7
CXCL13 4q21 BLC, BCA1, ANGIE, BCA-1, BLR1L, ANGIE2, SCYB13 -CXCL13 and Breast Cancer
7
PRC1 15q26.1 ASE1 -PRC1 and Breast Cancer
7
PCGF2 17q12 MEL-18, RNF110, ZNF144 -PCGF2 and Breast Cancer
7
UHRF1 19p13.3 Np95, hNP95, ICBP90, RNF106, hUHRF1, huNp95 -UHRF1 and Breast Cancer
7
EPHB4 7q22 HTK, MYK1, TYRO11 -EPHB4 and Breast Cancer
7
MAP2K2 19p13.3 CFC4, MEK2, MKK2, MAPKK2, PRKMK2 -MAP2K2 and Breast Cancer
7
TNFSF15 9q32 TL1, TL1A, VEGI, VEGI192A -TNFSF15 and Breast Cancer
7
LOXL2 8p21.3 LOR2, WS9-14 -LOXL2 and Breast Cancer
7
YY1AP1 1q22 YAP, HCCA1, HCCA2, YY1AP -YY1AP1 and Breast Cancer
7
YAP1 11q13 YAP, YKI, COB1, YAP2, YAP65 -YAP1 and Breast Cancer
7
E2F5 8q21.2 E2F-5 -E2F5 and Breast Cancer
7
NAV1 1q32.3 POMFIL3, UNC53H1, STEERIN1 -NAV1 and Breast Cancer
7
MYOD1 11p15.4 PUM, MYF3, MYOD, bHLHc1 -MYOD1 and Breast Cancer
7
YWHAZ 8q23.1 HEL4, YWHAD, KCIP-1, HEL-S-3, 14-3-3-zeta -YWHAZ and Breast Cancer
7
MTA2 11q12-q13.1 PID, MTA1L1 -MTA2 and Breast Cancer
7
TNFAIP3 6q23 A20, OTUD7C, TNFA1P2 -TNFAIP3 and Breast Cancer
6
PER1 17p13.1 PER, hPER, RIGUI -PER1 and Breast Cancer
6
IL6ST 5q11.2 CD130, GP130, CDW130, IL-6RB -IL6ST and Breast Cancer
6
NBR1 17q21.31 IAI3B, M17S2, MIG19, 1A1-3B -NBR1 and Breast Cancer
6
PTPRG 3p21-p14 PTPG, HPTPG, RPTPG, R-PTP-GAMMA -PTPRG and Breast Cancer
6
DMBT1 10q26.13 GP340, muclin -DMBT1 and Breast Cancer
6
HOXA10 7p15.2 PL, HOX1, HOX1H, HOX1.8 -HOXA10 and Breast Cancer
6
NEDD9 6p24.2 CAS2, CASL, HEF1, CAS-L, CASS2 -NEDD9 and Breast Cancer
6
DACH1 13q22 DACH -DACH1 and Breast Cancer
6
FGF7 15q21.2 KGF, HBGF-7 -FGF7 and Breast Cancer
6
BCAS1 20q13.2 AIBC1, NABC1 -BCAS1 and Breast Cancer
6
WHSC1L1 8p11.2 NSD3, pp14328 -WHSC1L1 and Breast Cancer
6
PRDM2 1p36.21 RIZ, KMT8, RIZ1, RIZ2, MTB-ZF, HUMHOXY1 -PRDM2 and Breast Cancer
6
ITGA6 2q31.1 CD49f, VLA-6, ITGA6B -ITGA6 and Breast Cancer
6
PER3 1p36.23 GIG13 -PER3 and Breast Cancer
6
MIF 22q11.23 GIF, GLIF, MMIF -MIF and Breast Cancer
6
KISS1R 19p13.3 HH8, CPPB1, GPR54, AXOR12, KISS-1R, HOT7T175 -KISS1R and Breast Cancer
6
CCR2 3p21.31 CKR2, CCR-2, CCR2A, CCR2B, CD192, CKR2A, CKR2B, CMKBR2, MCP-1-R, CC-CKR-2 -CCR2 and Breast Cancer
6
SHMT1 17p11.2 SHMT, CSHMT -SHMT1 and Breast Cancer
6
TRIO 5p15.2 tgat, ARHGEF23 -TRIO and Breast Cancer
6
HNRNPA2B1 7p15 RNPA2, HNRPA2, HNRPB1, SNRPB1, HNRNPA2, HNRNPB1, IBMPFD2, HNRPA2B1 -HNRNPA2B1 and Breast Cancer
6
ST7 7q31.2 HELG, RAY1, SEN4, TSG7, ETS7q, FAM4A, FAM4A1 -ST7 and Breast Cancer
6
CUL3 2q36.2 CUL-3, PHA2E -CUL3 and Breast Cancer
6
EEF1A2 20q13.3 HS1, STN, EF1A, STNL, EEF1AL, EF-1-alpha-2 -EEF1A2 and Breast Cancer
6
TNKS 8p23.1 TIN1, ARTD5, PARPL, TINF1, TNKS1, pART5, PARP5A, PARP-5a -TNKS and Breast Cancer
6
STC1 8p21.2 STC -STC1 and Breast Cancer
6
TNFRSF10C 8p22-p21 LIT, DCR1, TRID, CD263, TRAILR3, TRAIL-R3, DCR1-TNFR -TNFRSF10C and Breast Cancer
6
CA12 15q22 CAXII, HsT18816 -CA12 and Breast Cancer
6
TACR1 2p12 SPR, NK1R, NKIR, TAC1R -TACR1 and Breast Cancer
6
HSPA8 11q24.1 LAP1, HSC54, HSC70, HSC71, HSP71, HSP73, LAP-1, NIP71, HEL-33, HSPA10, HEL-S-72p -HSPA8 and Breast Cancer
6
EBAG9 8q23 EB9, PDAF -EBAG9 and Breast Cancer
6
ARL11 13q14.2 ARLTS1 -ARL11 and Breast Cancer
6
CHUK 10q24-q25 IKK1, IKKA, IKBKA, TCF16, NFKBIKA, IKK-alpha -CHUK and Breast Cancer
6
PLAT 8p12 TPA, T-PA -PLAT and Breast Cancer
6
TANK 2q24.2 ITRAF, TRAF2, I-TRAF -TANK and Breast Cancer
6
CD36 7q11.2 FAT, GP4, GP3B, GPIV, CHDS7, PASIV, SCARB3, BDPLT10 -CD36 and Breast Cancer
6
MIR107 10q23.31 MIRN107, miR-107 -MicroRNA mir-107 and Breast Cancer
6
SKI 1p36.33 SGS, SKV -SKI and Breast Cancer
6
CMBL 5p15.2 JS-1 -CMBL and Breast Cancer
6
ABCC5 3q27 MRP5, SMRP, ABC33, MOATC, MOAT-C, pABC11, EST277145 -ABCC5 and Breast Cancer
6
ETV6 12p13 TEL, THC5, TEL/ABL Translocation
-t(12;15)(p13;q25) ETV6-NTRK3 in Breast Cancer
6
SLC19A2 1q23.3 TC1, THT1, TRMA, THMD1, THTR1 -SLC19A2 and Breast Cancer
6
ITGA4 2q31.3 IA4, CD49D -ITGA4 and Breast Cancer
6
ADAM10 15q22 RAK, kuz, AD10, AD18, MADM, CD156c, HsT18717 -ADAM10 and Breast Cancer
6
SOCS2 12q CIS2, SSI2, Cish2, SSI-2, SOCS-2, STATI2 -SOCS2 and Breast Cancer
6
ADH1B 4q23 ADH2, HEL-S-117 -ADH1B and Breast Cancer
6
GDNF 5p13.1-p12 ATF1, ATF2, HSCR3, HFB1-GDNF -GDNF and Breast Cancer
6
WNT2 7q31.2 IRP, INT1L1 -WNT2 and Breast Cancer
6
NUMB 14q24.3 S171, C14orf41, c14_5527 -NUMB and Breast Cancer
6
IL4 5q31.1 BSF1, IL-4, BCGF1, BSF-1, BCGF-1 -IL4 and Breast Cancer
6
MCM2 3q21 BM28, CCNL1, CDCL1, cdc19, D3S3194, MITOTIN -MCM2 and Breast Cancer
6
CD46 1q32 MCP, TLX, AHUS2, MIC10, TRA2.10 -CD46 and Breast Cancer
6
WNT4 1p36.23-p35.1 WNT-4, SERKAL -WNT4 and Breast Cancer
6
SQSTM1 5q35 p60, p62, A170, OSIL, PDB3, ZIP3, p62B -SQSTM1 and Breast Cancer
6
ROBO1 3p12 SAX3, DUTT1 -ROBO1 and Breast Cancer
6
IL2 4q26-q27 IL-2, TCGF, lymphokine -IL2 and Breast Cancer
6
KRT8 12q13 K8, KO, CK8, CK-8, CYK8, K2C8, CARD2 -KRT8 and Breast Cancer
6
MMP8 11q22.3 HNC, CLG1, MMP-8, PMNL-CL -MMP8 and Breast Cancer
6
KLK5 19q13.33 SCTE, KLKL2, KLK-L2 -KLK5 and Breast Cancer
6
RAC3 17q25.3 -RAC3 and Breast Cancer
6
TGFBR3 1p33-p32 BGCAN, betaglycan -TGFBR3 and Breast Cancer
6
WISP1 8q24.22 CCN4, WISP1c, WISP1i, WISP1tc -WISP1 and Breast Cancer
6
ABCC3 17q22 MLP2, MRP3, ABC31, MOAT-D, cMOAT2, EST90757 -ABCC3 and Breast Cancer
6
PMP22 17p12 DSS, HNPP, CMT1A, CMT1E, GAS-3, Sp110, HMSNIA -PMP22 and Breast Cancer
6
NOD2 16q21 CD, ACUG, BLAU, IBD1, NLRC2, NOD2B, CARD15, CLR16.3, PSORAS1 -NOD2 and Breast Cancer
6
DDR1 6p21.3 CAK, DDR, NEP, HGK2, PTK3, RTK6, TRKE, CD167, EDDR1, MCK10, NTRK4, PTK3A -DDR1 and Breast Cancer
6
LTA 6p21.3 LT, TNFB, TNFSF1 -LTA and Breast Cancer
6
PTPN1 20q13.1-q13.2 PTP1B -PTPN1 and Breast Cancer
6
LYVE1 11p15 HAR, XLKD1, LYVE-1, CRSBP-1 -LYVE1 and Breast Cancer
6
HOTAIR 12q13.13 HOXAS, HOXC-AS4, HOXC11-AS1, NCRNA00072 -HOTAIR and Breast Cancer
6
SIN3A 15q24.2 -SIN3A and Breast Cancer
6
CHEK1 11q24.2 CHK1 -CHEK1 and Breast Cancer
6
CYP11A1 15q23-q24 CYP11A, CYPXIA1, P450SCC -CYP11A1 and Breast Cancer
6
PYGM 11q12-q13.2 -PYGM and Breast Cancer
6
SLIT2 4p15.2 SLIL3, Slit-2 -SLIT2 and Breast Cancer
6
LGALS1 22q13.1 GBP, GAL1 -LGALS1 and Breast Cancer
6
SAT2 17p13.1 SSAT2 -SAT2 and Breast Cancer
5
MAD1L1 7p22 MAD1, PIG9, TP53I9, TXBP181 -MAD1L1 and Breast Cancer
5
BIRC3 11q22 AIP1, API2, MIHC, CIAP2, HAIP1, HIAP1, MALT2, RNF49, c-IAP2 -BIRC3 and Breast Cancer
5
ING4 12p13.31 my036, p29ING4 -ING4 and Breast Cancer
5
CCNA1 13q12.3-q13 CT146 -CCNA1 and Breast Cancer
5
IGFBP7 4q12 AGM, PSF, TAF, FSTL2, IBP-7, MAC25, IGFBP-7, RAMSVPS, IGFBP-7v, IGFBPRP1 -IGFBP7 and Breast Cancer
5
SKIL 3q26 SNO, SnoA, SnoI, SnoN -SKIL and Breast Cancer
5
TP53INP1 8q22 SIP, Teap, p53DINP1, TP53DINP1, TP53INP1A, TP53INP1B -TP53INP1 and Breast Cancer
5
CKS1B 1q21.2 CKS1, ckshs1, PNAS-16, PNAS-18 -CKS1B and Breast Cancer
5
TXNRD1 12q23-q24.1 TR, TR1, TXNR, TRXR1, GRIM-12 -TXNRD1 and Breast Cancer
5
CRY2 11p11.2 HCRY2, PHLL2 -CRY2 and Breast Cancer
5
SFRP5 10q24.1 SARP3 -SFRP5 and Breast Cancer
5
CALU 7q32.1 -CALU and Breast Cancer
5
LASP1 17q11-q21.3 MLN50, Lasp-1 -LASP1 and Breast Cancer
5
SULF2 20q13.12 HSULF-2 -SULF2 and Breast Cancer
5
NDRG2 14q11.2 SYLD -NDRG2 and Breast Cancer
5
CCR4 3p24 CKR4, K5-5, CD194, CMKBR4, ChemR13, CC-CKR-4, HGCN:14099 -CCR4 and Breast Cancer
5
CTBP1 4p16 BARS -CTBP1 and Breast Cancer
5
LRP6 12p13.2 ADCAD2 -LRP6 and Breast Cancer
5
SIRT3 11p15.5 SIR2L3 -SIRT3 and Breast Cancer
5
TAGLN 11q23.2 SM22, SMCC, TAGLN1, WS3-10 -TAGLN and Breast Cancer
5
MIRLET7G 3p21.1 LET7G, let-7g, MIRNLET7G, hsa-let-7g -MicroRNA let-7g and Breast Cancer
5
FOSB 19q13.32 AP-1, G0S3, GOS3, GOSB -FOSB and Breast Cancer
5
MTHFD1 14q24 MTHFC, MTHFD -MTHFD1 and Breast Cancer
5
RAG2 11p13 RAG-2 -RAG2 and Breast Cancer
5
TRADD 16q22 Hs.89862 -TRADD and Breast Cancer
5
TLR2 4q32 TIL4, CD282 -TLR2 and Breast Cancer
5
NUMA1 11q13 NUMA, NMP-22 -NUMA1 and Breast Cancer
5
UGT2B15 4q13 HLUG4, UGT2B8, UDPGTH3, UDPGT 2B8, UDPGT2B15 -UGT2B15 and Breast Cancer
5
GNRHR 4q21.2 HH7, GRHR, LRHR, LHRHR, GNRHR1 -GNRHR and Breast Cancer
5
ACTA2 10q23.3 AAT6, ACTSA, MYMY5 -ACTA2 and Breast Cancer
5
POLD1 19q13.3 CDC2, MDPL, POLD, CRCS10 -POLD1 and Breast Cancer
5
PTPRF 1p34 LAR, BNAH2 -PTPRF and Breast Cancer
5
MAPK14 6p21.3-p21.2 RK, p38, CSBP, EXIP, Mxi2, CSBP1, CSBP2, CSPB1, PRKM14, PRKM15, SAPK2A, p38ALPHA -MAPK14 and Breast Cancer
5
NGFR 17q21-q22 CD271, p75NTR, TNFRSF16, p75(NTR), Gp80-LNGFR -NGFR and Breast Cancer
5
LINC00632 Xq27.1 -RP1-177G6.2 and Breast Cancer
5
ARNTL 11p15 TIC, JAP3, MOP3, BMAL1, PASD3, BMAL1c, bHLHe5 -ARNTL and Breast Cancer
5
FOSL1 11q13 FRA, FRA1, fra-1 -FOSL1 and Breast Cancer
5
IER3 6p21.3 DIF2, IEX1, PRG1, DIF-2, GLY96, IEX-1, IEX-1L -IER3 and Breast Cancer
5
HYAL1 3p21.31 MPS9, NAT6, LUCA1, HYAL-1 -HYAL1 and Breast Cancer
5
DLL4 15q14 hdelta2 -DLL4 and Breast Cancer
5
CCNG2 4q21.1 -CCNG2 and Breast Cancer
5
TPD52L1 6q22-q23 D53, hD53 -TPD52L1 and Breast Cancer
5
EREG 4q13.3 ER -EREG and Breast Cancer
5
PGK1 Xq13.3 PGKA, MIG10, HEL-S-68p -PGK1 and Breast Cancer
5
PPP2R1B 11q23.2 PR65B, PP2A-Abeta -PPP2R1B and Breast Cancer
5
GSTO2 10q25.1 GSTO 2-2, bA127L20.1 -GSTO2 and Breast Cancer
5
SULF1 8q13.2 SULF-1, HSULF-1 -SULF1 and Breast Cancer
5
CASP4 11q22.2-q22.3 TX, ICH-2, Mih1/TX, ICEREL-II, ICE(rel)II -CASP4 and Breast Cancer
5
USF1 1q22-q23 UEF, FCHL, MLTF, FCHL1, MLTFI, HYPLIP1, bHLHb11 -USF1 and Breast Cancer
5
SOX17 8q11.23 VUR3 -SOX17 and Breast Cancer
5
HIPK2 7q34 PRO0593 -HIPK2 and Breast Cancer
5
S100A2 1q21 CAN19, S100L -S100A2 and Breast Cancer
5
EGLN1 1q42.1 HPH2, PHD2, SM20, ECYT3, HALAH, HPH-2, HIFPH2, ZMYND6, C1orf12, HIF-PH2 -EGLN1 and Breast Cancer
5
PTPRJ 11p11.2 DEP1, SCC1, CD148, HPTPeta, R-PTP-ETA -PTPRJ and Breast Cancer
5
ALOX5 10q11.2 5-LO, 5LPG, LOG5, 5-LOX -ALOX5 and Breast Cancer
5
TYRO3 15q15 BYK, Dtk, RSE, Rek, Sky, Tif, Etk-2 -TYRO3 and Breast Cancer
5
LRIG1 3p14 LIG1, LIG-1 -LRIG1 and Breast Cancer
5
LARS 5q32 LRS, LEUS, LFIS, ILFS1, LARS1, LEURS, PIG44, RNTLS, HSPC192, hr025Cl -LARS and Breast Cancer
5
ISG15 1p36.33 G1P2, IP17, UCRP, IFI15, IMD38, hUCRP -ISG15 and Breast Cancer
5
KLK4 19q13.41 ARM1, EMSP, PSTS, AI2A1, EMSP1, KLK-L1, PRSS17, kallikrein -KLK4 and Breast Cancer
5
REST 4q12 XBR, NRSF -REST and Breast Cancer
5
ANGPTL4 19p13.3 NL2, ARP4, FIAF, HARP, PGAR, HFARP, TGQTL, UNQ171, pp1158, ANGPTL2 -ANGPTL4 and Breast Cancer
5
CXCL14 5q31 KEC, KS1, BMAC, BRAK, NJAC, MIP2G, MIP-2g, SCYB14 -CXCL14 and Breast Cancer
5
CXCR1 2q35 C-C, CD128, CD181, CKR-1, IL8R1, IL8RA, CMKAR1, IL8RBA, CDw128a, C-C-CKR-1 -CXCR1 and Breast Cancer
5
RALGDS 9q34.3 RGF, RGDS, RalGEF -RALGDS and Breast Cancer
5
TPM1 15q22.1 CMH3, TMSA, CMD1Y, LVNC9, C15orf13, HTM-alpha -TPM1 and Breast Cancer
5
FHL2 2q12.2 DRAL, AAG11, FHL-2, SLIM3, SLIM-3 -FHL2 and Breast Cancer
5
SCRIB 8q24.3 CRIB1, SCRB1, SCRIB1, Vartul -SCRIB and Breast Cancer
5
BANP 16q24 BEND1, SMAR1, SMARBP1 -BANP and Breast Cancer
5
CEACAM6 19q13.2 NCA, CEAL, CD66c -CEACAM6 and Breast Cancer
5
GSTO1 10q25.1 P28, SPG-R, GSTO 1-1, GSTTLp28, HEL-S-21 -GSTO1 and Breast Cancer
5
CDK7 5q12.1 CAK1, HCAK, MO15, STK1, CDKN7, p39MO15 -CDK7 and Breast Cancer
5
TLR1 4p14 TIL, CD281, rsc786, TIL. LPRS5 -TLR1 and Breast Cancer
5
TPX2 20q11.2 DIL2, p100, DIL-2, HCTP4, FLS353, HCA519, REPP86, C20orf1, C20orf2, GD:C20orf1 -TPX2 and Breast Cancer
5
APOB 2p24-p23 FLDB, LDLCQ4 -APOB and Breast Cancer
5
CLDN7 17p13.1 CLDN-7, CEPTRL2, CPETRL2, Hs.84359, claudin-1 -CLDN7 and Breast Cancer
5
GAS6 13q34 AXSF, AXLLG -GAS6 and Breast Cancer
5
CCL20 2q36.3 CKb4, LARC, ST38, MIP3A, Exodus, MIP-3a, SCYA20, MIP-3-alpha -CCL20 and Breast Cancer
5
SPHK1 17q25.2 SPHK -SPHK1 and Breast Cancer
5
KLLN 10q23 CWS4, KILLIN -KLLN and Breast Cancer
5
TXNIP 1q21.1 THIF, VDUP1, HHCPA78, EST01027 -TXNIP and Breast Cancer
5
CD163 12p13.3 M130, MM130 -CD163 and Breast Cancer
5
CCL21 9p13 ECL, SLC, CKb9, TCA4, 6Ckine, SCYA21 -CCL21 and Breast Cancer
5
XRCC6 22q13.2 ML8, KU70, TLAA, CTC75, CTCBF, G22P1 -XRCC6 and Breast Cancer
5
IL15 4q31 IL-15 -IL15 and Breast Cancer
5
POU1F1 3p11 PIT1, CPHD1, GHF-1, Pit-1, POU1F1a -POU1F1 and Breast Cancer
5
MVP 16p11.2 LRP, VAULT1 -MVP and Breast Cancer
5
FRZB 2q32.1 FRE, OS1, FZRB, hFIZ, FRITZ, FRP-3, FRZB1, SFRP3, SRFP3, FRZB-1, FRZB-PEN -FRZB and Breast Cancer
5
SEMA3B 3p21.3 SemA, SEMA5, SEMAA, semaV, LUCA-1 -SEMA3B and Breast Cancer
5
DRD2 11q23 D2R, D2DR -DRD2 and Breast Cancer
5
CYBA 16q24 p22-PHOX -CYBA and Breast Cancer
5
PRDX1 1p34.1 PAG, PAGA, PAGB, PRX1, PRXI, MSP23, NKEFA, TDPX2, NKEF-A -PRDX1 and Breast Cancer
5
PTMS 12p13 ParaT -PTMS and Breast Cancer
5
MAGEA4 Xq28 CT1.4, MAGE4, MAGE4A, MAGE4B, MAGE-41, MAGE-X2 -MAGEA4 and Breast Cancer
5
AMFR 16q21 GP78, RNF45 -AMFR and Breast Cancer
5
DDIT4 10q22.1 Dig2, REDD1, REDD-1 -DDIT4 and Breast Cancer
5
DKC1 Xq28 DKC, CBF5, DKCX, NAP57, NOLA4, XAP101 -DKC1 and Breast Cancer
5
ST14 11q24-q25 HAI, MTSP1, SNC19, ARCI11, MT-SP1, PRSS14, TADG15, TMPRSS14 -ST14 and Breast Cancer
4
KDM4C 9p24.1 GASC1, JHDM3C, JMJD2C, TDRD14C -KDM4C and Breast Cancer
4
RECQL4 8q24.3 RECQ4 -RECQL4 and Breast Cancer
4
FGR 1p36.2-p36.1 SRC2, c-fgr, c-src2, p55-Fgr, p58-Fgr, p55c-fgr, p58c-fgr -FGR and Breast Cancer
4
AQP1 7p14 CO, CHIP28, AQP-CHIP -AQP1 and Breast Cancer
4
EGLN3 14q13.1 PHD3, HIFPH3, HIFP4H3 -EGLN3 and Breast Cancer
4
MYCN 2p24.3 NMYC, ODED, MODED, N-myc, bHLHe37 -MYCN and Breast Cancer
4
AVPR1B 1q32 AVPR3 -AVPR1B and Breast Cancer
4
TBK1 12q14.1 NAK, T2K -TBK1 and Breast Cancer
4
CD151 11p15.5 GP27, MER2, RAPH, SFA1, PETA-3, TSPAN24 -CD151 and Breast Cancer
4
NOX1 Xq22 MOX1, NOH1, NOH-1, GP91-2 -NOX1 and Breast Cancer
4
HOXC11 12q13.3 HOX3H -HOXC11 and Breast Cancer
4
FLNC 7q32-q35 ABPA, ABPL, FLN2, MFM5, MPD4, ABP-280, ABP280A -FLNC and Breast Cancer
4
SMARCA2 9p22.3 BRM, SNF2, SWI2, hBRM, NCBRS, Sth1p, BAF190, SNF2L2, SNF2LA, hSNF2a -SMARCA2 and Breast Cancer
4
PPIA 7p13 CYPA, CYPH, HEL-S-69p -PPIA and Breast Cancer
4
MELK 9p13.2 HPK38 -MELK and Breast Cancer
4
PLAGL1 6q24-q25 ZAC, LOT1, ZAC1 -PLAGL1 and Breast Cancer
4
MUC5B 11p15.5 MG1, MUC5, MUC9, MUC-5B -MUC5B and Breast Cancer
4
SLC9A1 1p36.1-p35 APNH, NHE1, LIKNS, NHE-1, PPP1R143 -SLC9A1 and Breast Cancer
4
PARK7 1p36.23 DJ1, DJ-1, HEL-S-67p -PARK7 and Breast Cancer
4
SMPD1 11p15.4-p15.1 ASM, NPD, ASMASE -SMPD1 and Breast Cancer
4
CXCR5 11q23.3 BLR1, CD185, MDR15 -CXCR5 and Breast Cancer
4
GNB2L1 5q35.3 H12.3, HLC-7, PIG21, RACK1, Gnb2-rs1 -GNB2L1 and Breast Cancer
4
THRA 17q11.2 AR7, EAR7, ERBA, CHNG6, ERBA1, NR1A1, THRA1, THRA2, ERB-T-1, c-ERBA-1 -THRA and Breast Cancer
4
RARRES3 11q23 RIG1, TIG3, HRSL4, HRASLS4, PLA1/2-3 -RARRES3 and Breast Cancer
4
HYAL2 3p21.3 LUCA2 -HYAL2 and Breast Cancer
4
PLA2G4A 1q25 PLA2G4, cPLA2-alpha -PLA2G4A and Breast Cancer
4
CASP5 11q22.2-q22.3 ICH-3, ICEREL-III, ICE(rel)III -CASP5 and Breast Cancer
4
CDK9 9q34.1 TAK, C-2k, CTK1, CDC2L4, PITALRE -CDK9 and Breast Cancer
4
LAPTM4B 8q22.1 LC27, LAPTM4beta -LAPTM4B and Breast Cancer
4
FSCN1 7p22 HSN, SNL, p55, FAN1 -FSCN1 and Breast Cancer
4
CX3CL1 16q13 NTN, NTT, CXC3, CXC3C, SCYD1, ABCD-3, C3Xkine, fractalkine, neurotactin -CX3CL1 and Breast Cancer
4
PHIP 6q14 ndrp, BRWD2, WDR11, DCAF14 -PHIP and Breast Cancer
4
TBX21 17q21.32 TBET, T-PET, T-bet, TBLYM -TBX21 and Breast Cancer
4
CTSL 9q21.33 MEP, CATL, CTSL1 -CTSL1 and Breast Cancer
4
BCL11A 2p16.1 EVI9, CTIP1, ZNF856, HBFQTL5, BCL11A-L, BCL11A-S, BCL11a-M, BCL11A-XL Amplification
Overexpression
-BCL11A Overexpression and Amplification Breast Cancer
4
NFATC2 20q13.2 NFAT1, NFATP -NFATC2 and Breast Cancer
4
FGF19 11q13.1 -FGF19 and Breast Cancer
4
ARID4A 14q23.1 RBP1, RBBP1, RBP-1, RBBP-1 -ARID4A and Breast Cancer
4
MINA 3q11.2 ROX, MDIG, NO52, MINA53 -MINA and Breast Cancer
4
IRAK2 3p25.3 IRAK-2 -IRAK2 and Breast Cancer
4
DUSP4 8p12-p11 TYP, HVH2, MKP2, MKP-2 -DUSP4 and Breast Cancer
4
SSTR1 14q13 SS1R, SS1-R, SRIF-2, SS-1-R -SSTR1 and Breast Cancer
4
BTG1 12q22 -BTG1 and Breast Cancer
4
MCM7 7q21.3-q22.1 MCM2, CDC47, P85MCM, P1CDC47, PNAS146, PPP1R104, P1.1-MCM3 -MCM7 and Breast Cancer
4
RAD54L 1p32 HR54, hHR54, RAD54A, hRAD54 -RAD54L and Breast Cancer
4
DUSP6 12q22-q23 HH19, MKP3, PYST1 -DUSP6 and Breast Cancer
4
MUC16 19p13.2 CA125 -MUC16 and Breast Cancer
4
NOV 8q24.1 CCN3, NOVh, IBP-9, IGFBP9, IGFBP-9 -NOV and Breast Cancer
4
CXCL16 17p13 SRPSOX, CXCLG16, SR-PSOX -CXCL16 and Breast Cancer
4
STRADA 17q23.3 LYK5, PMSE, Stlk, STRAD, NY-BR-96 -STRADA and Breast Cancer
4
GNL3 3p21.1 NS, E2IG3, NNP47, C77032 -GNL3 and Breast Cancer
4
RBP1 3q23 CRBP, RBPC, CRBP1, CRBPI, CRABP-I -RBP1 and Breast Cancer
4
ITGB2 21q22.3 LAD, CD18, MF17, MFI7, LCAMB, LFA-1, MAC-1 -ITGB2 and Breast Cancer
4
TDGF1 3p21.31 CR, CRGF, CRIPTO -TDGF1 and Breast Cancer
4
HTATIP2 11p15.1 CC3, TIP30, SDR44U1 -HTATIP2 and Breast Cancer
4
CXCL9 4q21 CMK, MIG, Humig, SCYB9, crg-10 -CXCL9 and Breast Cancer
4
WNT11 11q13.5 HWNT11 -WNT11 and Breast Cancer
4
SEMA3A 7p12.1 HH16, SemD, COLL1, SEMA1, SEMAD, SEMAL, coll-1, Hsema-I, SEMAIII, Hsema-III -SEMA3A and Breast Cancer
4
SPRY1 4q28.1 hSPRY1 -SPRY1 and Breast Cancer
4
TRAF1 9q33-q34 EBI6, MGC:10353 -TRAF1 and Breast Cancer
4
BMPR1B 4q22-q24 ALK6, ALK-6, CDw293 -BMPR1B and Breast Cancer
4
CASP6 4q25 MCH2 -CASP6 and Breast Cancer
4
MX1 21q22.3 MX, MxA, IFI78, IFI-78K -MX1 and Breast Cancer
4
IL6R 1q21 IL6Q, gp80, CD126, IL6RA, IL6RQ, IL-6RA, IL-6R-1 -IL6R and Breast Cancer
4
KIAA1524 3q13.13 p90, CIP2A -KIAA1524 and Breast Cancer
4
KRT14 17q21.2 K14, NFJ, CK14, EBS3, EBS4 -KRT14 and Breast Cancer
4
BCL2L12 19q13.3 -BCL2L12 and Breast Cancer
4
CD69 12p13 AIM, EA1, MLR-3, CLEC2C, GP32/28, BL-AC/P26 -CD69 and Breast Cancer
4
GMNN 6p22.3 Gem -GMNN and Breast Cancer
4
LRP1 12q13.3 APR, LRP, A2MR, CD91, APOER, LRP1A, TGFBR5, IGFBP3R -LRP1 and Breast Cancer
4
CXCL5 4q13.3 SCYB5, ENA-78 -CXCL5 and Breast Cancer
4
GRASP 12q13.13 TAMALIN -GRASP and Breast Cancer
4
AVPR1A 12q14-q15 V1aR, AVPR1, AVPR V1a -AVPR1A and Breast Cancer
4
GRM1 6q24 MGLU1, GPRC1A, MGLUR1, SCAR13, PPP1R85 -GRM1 and Breast Cancer
4
ARHGDIB 12p12.3 D4, GDIA2, GDID4, LYGDI, Ly-GDI, RAP1GN1, RhoGDI2 -ARHGDIB and Breast Cancer
4
ANO1 11q13.3 DOG1, TAOS2, ORAOV2, TMEM16A -ANO1 and Breast Cancer
4
PRKCD 3p21.31 MAY1, PKCD, ALPS3, CVID9, nPKC-delta -PRKCD and Breast Cancer
4
FABP7 6q22-q23 MRG, BLBP, FABPB, B-FABP, LTR2-FABP7 -FABP7 and Breast Cancer
4
SSTR5 16p13.3 SS-5-R -SSTR5 and Breast Cancer
4
HPSE 4q21.3 HPA, HPA1, HPR1, HSE1, HPSE1 -HPSE and Breast Cancer
4
LZTS1 8p22 F37, FEZ1 -LZTS1 and Breast Cancer
4
ABCA1 9q31.1 TGD, ABC1, CERP, ABC-1, HDLDT1 -ABCA1 and Breast Cancer
4
TFRC 3q29 T9, TR, TFR, p90, CD71, TFR1, TRFR -TFRC and Breast Cancer
4
CCNG1 5q32-q34 CCNG -CCNG1 and Breast Cancer
4
CCL3 17q12 MIP1A, SCYA3, G0S19-1, LD78ALPHA, MIP-1-alpha -CCL3 and Breast Cancer
4
CD276 15q23-q24 B7H3, B7-H3, B7RP-2, 4Ig-B7-H3 -CD276 and Breast Cancer
4
RBX1 22q13.2 ROC1, RNF75, BA554C12.1 -RBX1 and Breast Cancer
4
PINX1 8p23 LPTL, LPTS -PINX1 and Breast Cancer
4
DAB2IP 9q33.1-q33.3 AIP1, AIP-1, AF9Q34, DIP1/2 -DAB2IP and Breast Cancer
4
MIR10A 17q21.32 MIRN10A, mir-10a, miRNA10A, hsa-mir-10a -miR-10a and Breast Cancer
4
TNFRSF10D 8p21 DCR2, CD264, TRUNDD, TRAILR4, TRAIL-R4 -TNFRSF10D and Breast Cancer
3
CHI3L1 1q32.1 GP39, ASRT7, GP-39, YKL40, CGP-39, YKL-40, YYL-40, HC-gp39, HCGP-3P, hCGP-39 -CHI3L1 and Breast Cancer
3
BAGE 21p11.1 not on ref BAGE1, CT2.1 -BAGE and Breast Cancer
3
LDHA 11p15.4 LDH1, LDHM, GSD11, PIG19, HEL-S-133P -LDHA and Breast Cancer
3
USP7 16p13.3 TEF1, HAUSP -USP7 and Breast Cancer
3
CDCP1 3p21.31 CD318, TRASK, SIMA135 -CDCP1 and Breast Cancer
3
MIRLET7I 12q14.1 LET7I, MIRNLET7I, hsa-let-7i -None and Breast Cancer
3
PRKCDBP 11p15.4 SRBC, HSRBC, CAVIN3, cavin-3 -PRKCDBP and Breast Cancer
3
WNT7A 3p25 -WNT7A and Breast Cancer
3
ATF6 1q23.3 ATF6A -ATF6 and Breast Cancer
3
TRAF6 11p12 RNF85, MGC:3310 -TRAF6 and Breast Cancer
3
MAGEB2 Xp21.3 DAM6, CT3.2, MAGE-XP-2 -MAGEB2 and Breast Cancer
3
NKX2-5 5q34 CSX, CSX1, VSD3, CHNG5, HLHS2, NKX2E, NKX2.5, NKX4-1 -NKX2-5 and Breast Cancer
3
STIM1 11p15.5 GOK, TAM, TAM1, IMD10, STRMK, D11S4896E -STIM1 and Breast Cancer
3
WWTR1 3q23-q24 TAZ -WWTR1 and Breast Cancer
3
SLC5A8 12q23.1 AIT, SMCT, SMCT1 -SLC5A8 and Breast Cancer
3
SNRPN 15q11.2 SMN, PWCR, SM-D, sm-N, RT-LI, HCERN3, SNRNP-N, SNURF-SNRPN -SNRPN and Breast Cancer
3
GALM 2p22.1 GLAT, IBD1, BLOCK25, HEL-S-63p -GALM and Breast Cancer
3
CASP2 7q34-q35 ICH1, NEDD2, CASP-2, NEDD-2, PPP1R57 -CASP2 and Breast Cancer
3
MYH9 22q13.1 MHA, FTNS, EPSTS, BDPLT6, DFNA17, NMMHCA, NMHC-II-A, NMMHC-IIA -MYH9 and Breast Cancer
3
MT1G 16q13 MT1, MT1K -MT1G and Breast Cancer
3
MSI1 12q24 -MSI1 and Breast Cancer
3
ROR1 1p31.3 NTRKR1, dJ537F10.1 -ROR1 and Breast Cancer
3
MAP2K6 17q24.3 MEK6, MKK6, MAPKK6, PRKMK6, SAPKK3, SAPKK-3 -MAP2K6 and Breast Cancer
3
LDLR 19p13.2 FH, FHC, LDLCQ2 -LDLR and Breast Cancer
3
PPARGC1A 4p15.1 LEM6, PGC1, PGC1A, PGC-1v, PPARGC1, PGC-1(alpha) -PPARGC1A and Breast Cancer
3
EPHA5 4q13.1 EK7, CEK7, EHK1, HEK7, EHK-1, TYRO4 -EPHA5 and Breast Cancer
3
CCL22 16q13 MDC, ABCD-1, SCYA22, STCP-1, DC/B-CK, A-152E5.1 -CCL22 and Breast Cancer
3
MTUS1 8p22 ATBP, ATIP, ICIS, MP44, MTSG1 -MTUS1 and Breast Cancer
3
CRY1 12q23-q24.1 PHLL1 -CRY1 and Breast Cancer
3
RARRES1 3q25.32 LXNL, TIG1, PERG-1 -RARRES1 and Breast Cancer
3
DLG1 3q29 hdlg, DLGH1, SAP97, SAP-97, dJ1061C18.1.1 -DLG1 and Breast Cancer
3
MALAT1 11q13.1 HCN, NEAT2, PRO2853, mascRNA, LINC00047, NCRNA00047 -MALAT1 and Breast Cancer
3
IL4R 16p12.1-p11.2 CD124, IL4RA, IL-4RA -IL4R and Breast Cancer
3
MT2A 16q13 MT2 -MT2A and Breast Cancer
3
IL23R 1p31.3 -IL23R and Breast Cancer
3
FCGR2A 1q23 CD32, FCG2, FcGR, CD32A, CDw32, FCGR2, IGFR2, FCGR2A1 -FCGR2A and Breast Cancer
3
CXCL11 4q21.2 IP9, H174, IP-9, b-R1, I-TAC, SCYB11, SCYB9B -CXCL11 and Breast Cancer
3
HRK 12q24.22 DP5, HARAKIRI -HRK and Breast Cancer
3
BOLL 2q33 BOULE -BOLL and Breast Cancer
3
SLCO1B3 12p12 LST3, HBLRR, LST-2, OATP8, OATP-8, OATP1B3, SLC21A8, LST-3TM13 -SLCO1B3 and Breast Cancer
3
CTCFL 20q13.31 CT27, BORIS, CTCF-T, HMGB1L1, dJ579F20.2 -CTCFL and Breast Cancer
3
MKL1 22q13 MAL, BSAC, MRTF-A -MKL1 and Breast Cancer
3
NNAT 20q11.2-q12 Peg5 -NNAT and Breast Cancer
3
CCNC 6q21 CycC -CCNC and Breast Cancer
3
FER 5q21 TYK3, PPP1R74, p94-Fer -FER and Breast Cancer
3
NOX4 11q14.2-q21 KOX, KOX-1, RENOX -NOX4 and Breast Cancer
3
SMYD3 1q44 KMT3E, ZMYND1, ZNFN3A1, bA74P14.1 -SMYD3 and Breast Cancer
3
RAD17 5q13 CCYC, R24L, RAD24, HRAD17, RAD17SP -RAD17 and Breast Cancer
3
NOTO 2p13.2 -NOTO and Breast Cancer
3
MME 3q25.2 NEP, SFE, CD10, CALLA -MME and Breast Cancer
3
PITX1 5q31.1 BFT, CCF, POTX, PTX1, LBNBG -PITX1 and Breast Cancer
3
BCL3 19q13.1-q13.2 BCL4, D19S37 -BCL3 and Breast Cancer
3
ESPL1 12q ESP1, SEPA -ESPL1 and Breast Cancer
3
PPP2R1A 19q13.41 PR65A, PP2AAALPHA, PP2A-Aalpha -PPP2R1A and Breast Cancer
3
CTSB 8p22 APPS, CPSB -CTSB and Breast Cancer
3
MAP3K8 10p11.23 COT, EST, ESTF, TPL2, AURA2, MEKK8, Tpl-2, c-COT -MAP3K8 and Breast Cancer
3
POU2F1 1q24.2 OCT1, OTF1, oct-1B -POU2F1 and Breast Cancer
3
LIPA 10q23.2-q23.3 LAL, CESD -LIPA and Breast Cancer
3
DLEC1 3p21.3 F56, DLC1, CFAP81 -DLEC1 and Breast Cancer
3
HPGD 4q34-q35 PGDH, PGDH1, PHOAR1, 15-PGDH, SDR36C1 -HPGD and Breast Cancer
3
GADD45B 19p13.3 MYD118, GADD45BETA -GADD45B and Breast Cancer
3
ENO1 1p36.2 NNE, PPH, MPB1, ENO1L1 -ENO1 and Breast Cancer
3
SRD5A1 5p15 S5AR 1 -SRD5A1 and Breast Cancer
3
ZBTB7A 19p13.3 LRF, FBI1, FBI-1, ZBTB7, ZNF857A, pokemon -ZBTB7A and Breast Cancer
3
WNT5B 12p13.3 -WNT5B and Breast Cancer
3
IMP3 15q24 BRMS2, MRPS4, C15orf12 -IMP3 and Breast Cancer
3
LRP1B 2q21.2 LRPDIT, LRP-DIT -LRP1B and Breast Cancer
3
MBD1 18q21 RFT, PCM1, CXXC3 -MBD1 and Breast Cancer
3
DEC1 9q32 CTS9 -DEC1 and Breast Cancer
3
SERPINC1 1q25.1 AT3, AT3D, ATIII, THPH7 -SERPINC1 and Breast Cancer
3
TLE1 9q21.32 ESG, ESG1, GRG1 -TLE1 and Breast Cancer
3
EPB41L3 18p11.32 4.1B, DAL1, DAL-1 -EPB41L3 and Breast Cancer
3
CKS2 9q22 CKSHS2 -CKS2 and Breast Cancer
3
LGALS4 19q13.2 GAL4, L36LBP -LGALS4 and Breast Cancer
3
FUT4 11q21 LeX, CD15, ELFT, FCT3A, FUTIV, SSEA-1, FUC-TIV -FUT4 and Breast Cancer
3
ROCK2 2p24 ROCK-II -ROCK2 and Breast Cancer
3
GPX2 14q24.1 GPRP, GPx-2, GI-GPx, GPRP-2, GPx-GI, GSHPx-2, GSHPX-GI -GPX2 and Breast Cancer
3
SOX18 20q13.33 HLTS -SOX18 and Breast Cancer
3
OCLN 5q13.1 BLCPMG, PPP1R115 -OCLN and Breast Cancer
3
RBM5 3p21.3 G15, H37, RMB5, LUCA15 -RBM5 and Breast Cancer
3
JAG2 14q32 HJ2, SER2 -JAG2 and Breast Cancer
3
MAP3K5 6q22.33 ASK1, MEKK5, MAPKKK5 -MAP3K5 and Breast Cancer
3
TRIM24 7q32-q34 PTC6, TF1A, TIF1, RNF82, TIF1A, hTIF1, TIF1ALPHA -TRIM24 and Breast Cancer
3
COL4A2 13q34 ICH, POREN2 -COL4A2 and Breast Cancer
3
HTRA1 10q26.3 L56, HtrA, ARMD7, ORF480, PRSS11, CARASIL -HTRA1 and Breast Cancer
3
CHAT 10q11.2 CMS6, CMS1A, CMS1A2, CHOACTASE -CHAT and Breast Cancer
3
PROX1 1q41 -PROX1 and Breast Cancer
3
ANGPT1 8q23.1 AGP1, AGPT, ANG1 -ANGPT1 and Breast Cancer
3
PRKCE 2p21 PKCE, nPKC-epsilon -PRKCE and Breast Cancer
3
RAG1 11p13 RAG-1, RNF74 -RAG1 and Breast Cancer
3
POLB 8p11.2 -POLB and Breast Cancer
3
FLT4 5q35.3 PCL, FLT41, LMPH1A, VEGFR3 -FLT4 and Breast Cancer
3
CD59 11p13 1F5, EJ16, EJ30, EL32, G344, MIN1, MIN2, MIN3, MIRL, HRF20, MACIF, MEM43, MIC11, MSK21, 16.3A5, HRF-20, MAC-IP, p18-20 -CD59 and Breast Cancer
3
GREM1 15q13.3 DRM, HMPS, MPSH, PIG2, CRAC1, CRCS4, DAND2, HMPS1, IHG-2, DUP15q, C15DUPq, GREMLIN, CKTSF1B1 -GREM1 and Breast Cancer
3
MUC3A 7q22 MUC3, MUC-3A -MUC3A and Breast Cancer
3
SLPI 20q12 ALP, MPI, ALK1, BLPI, HUSI, WAP4, WFDC4, HUSI-I -SLPI and Breast Cancer
3
AKAP9 7q21-q22 LQT11, PRKA9, AKAP-9, CG-NAP, YOTIAO, AKAP350, AKAP450, PPP1R45, HYPERION, MU-RMS-40.16A -AKAP9 and Breast Cancer
3
DGCR8 22q11.2 Gy1, pasha, DGCRK6, C22orf12 -DGCR8 and Breast Cancer
3
RAD23B 9q31.2 P58, HR23B, HHR23B -RAD23B and Breast Cancer
3
ROCK1 18q11.1 ROCK-I, P160ROCK -ROCK1 and Breast Cancer
3
GALT 9p13 -GALT and Breast Cancer
2
PCM1 8p22-p21.3 PTC4 -PCM1 and Breast Cancer
2
ABCB5 7p21.1 ABCB5beta, EST422562, ABCB5alpha -ABCB5 and Breast Cancer
2
ARF1 1q42 -ARF1 and Breast Cancer
2
HSD11B1 1q32-q41 HDL, 11-DH, HSD11, HSD11B, HSD11L, CORTRD2, SDR26C1, 11-beta-HSD1 -HSD11B1 and Breast Cancer
2
AKAP13 15q24-q25 BRX, LBC, p47, HA-3, Ht31, c-lbc, PRKA13, AKAP-13, AKAP-Lbc, ARHGEF13, PROTO-LB, PROTO-LBC -AKAP13 and Breast Cancer
2
HSP90AA1 14q32.33 EL52, HSPN, LAP2, HSP86, HSPC1, HSPCA, Hsp89, Hsp90, LAP-2, HSP89A, HSP90A, HSP90N, HSPCAL1, HSPCAL4 -HSP90AA1 and Breast Cancer
2
TSPO 22q13.31 DBI, IBP, MBR, PBR, PBS, BPBS, BZRP, PKBS, PTBR, mDRC, pk18 -TSPO and Breast Cancer
2
MIR34A 1p36.22 mir-34, MIRN34A, miRNA34A -MIR34A and Breast Cancer
2
GJB2 13q11-q12 HID, KID, PPK, CX26, DFNA3, DFNB1, NSRD1, DFNA3A, DFNB1A -GJB2 and Breast Cancer
2
GJA1 6q22.31 HSS, CMDR, CX43, GJAL, ODDD, AVSD3, HLHS1 -GJA1 and Breast Cancer
2
TRIM27 6p22 RFP, RNF76 -TRIM27 and Breast Cancer
2
EPHA1 7q34 EPH, EPHT, EPHT1 -EPHA1 and Breast Cancer
2
MGEA5 10q24.1-q24.3 OGA, MEA5, NCOAT -MGEA5 and Breast Cancer
2
MIR10B 2q31.1 MIRN10B, mir-10b, miRNA10B, hsa-mir-10b -MIR10B and Breast Cancer
2
TLR6 4p14 CD286 -TLR6 and Breast Cancer
2
ACVRL1 12q13.13 HHT, ALK1, HHT2, ORW2, SKR3, ALK-1, TSR-I, ACVRLK1 -ACVRL1 and Breast Cancer
2
GLIPR1 12q21.2 GLIPR, RTVP1, CRISP7 -GLIPR1 and Breast Cancer
2
GUSB 7q21.11 BG, MPS7 -GUSB and Breast Cancer
2
C2orf40 2q12.2 ECRG4 -C2orf40 and Breast Cancer
2
PRDX6 1q25.1 PRX, p29, AOP2, 1-Cys, NSGPx, aiPLA2, HEL-S-128m -PRDX6 and Breast Cancer
2
MAX 14q23 bHLHd4 -MAX and Breast Cancer
2
ACSL3 2q34-q35 ACS3, FACL3, PRO2194 -ACSL3 and Breast Cancer
2
RAP1GDS1 4q23-q25 GDS1, SmgGDS -RAP1GDS1 and Breast Cancer
2
RABEP1 17p13.2 RAB5EP, RABPT5 -RABEP1 and Breast Cancer
2
UCP2 11q13 UCPH, BMIQ4, SLC25A8 -UCP2 and Breast Cancer
2
TTL 2q13 -TTL and Breast Cancer
2
ODC1 2p25 ODC -ODC1 and Breast Cancer
2
VCAM1 1p32-p31 CD106, INCAM-100 -VCAM1 and Breast Cancer
2
MYCBP 1p33-p32.2 AMY-1 -MYCBP and Breast Cancer
2
CD1D 1q23.1 R3, CD1A -CD1D and Breast Cancer
2
PTPRK 6q22.2-q22.3 R-PTP-kappa -PTPRK and Breast Cancer
2
SDC4 20q12 SYND4 -SDC4 and Breast Cancer
2
ATP7A Xq21.1 MK, MNK, DSMAX, SMAX3 -ATP7A and Breast Cancer
2
IL32 16p13.3 NK4, TAIF, TAIFa, TAIFb, TAIFc, TAIFd, IL-32beta, IL-32alpha, IL-32delta, IL-32gamma -IL32 and Breast Cancer
2
PAWR 12q21 PAR4, Par-4 -PAWR and Breast Cancer
2
CTDSPL 3p21.3 PSR1, SCP3, HYA22, RBSP3, C3orf8 -CTDSPL and Breast Cancer
2
MIR1258 2q31.3 MIRN1258, mir-1258, hsa-mir-1258 -MicroRNA miR-1258 and Breast Cancer
2
LIMD1 3p21.3 -LIMD1 and Breast Cancer
2
PERP 6q24 THW, KCP1, PIGPC1, KRTCAP1, dJ496H19.1 -PERP and Breast Cancer
2
IL1RL1 2q12 T1, ST2, DER4, ST2L, ST2V, FIT-1, IL33R -IL1RL1 and Breast Cancer
2
FEZ1 11q24.2 -FEZ1 and Breast Cancer
2
TPM4 19p13.1 HEL-S-108 -TPM4 and Breast Cancer
2
TP53BP2 1q41 BBP, 53BP2, ASPP2, P53BP2, PPP1R13A -TP53BP2 and Breast Cancer
2
SOX5 12p12.1 L-SOX5, L-SOX5B, L-SOX5F -SOX5 and Breast Cancer
2
HAS3 16q22.1 -HAS3 and Breast Cancer
2
RNF217-AS1 6q22.33 STL -STL and Breast Cancer
2
SLC22A18 11p15.5 HET, ITM, BWR1A, IMPT1, TSSC5, ORCTL2, BWSCR1A, SLC22A1L, p45-BWR1A -SLC22A18 and Breast Cancer
2
PATZ1 22q12.2 ZSG, MAZR, PATZ, RIAZ, ZBTB19, ZNF278, dJ400N23 -PATZ1 and Breast Cancer
2
USP6 17p13 HRP1, TRE2, TRE17, Tre-2, TRESMCR, USP6-short -USP6 and Breast Cancer
2
AGTR2 Xq22-q23 AT2, ATGR2, MRX88 -AGTR2 and Breast Cancer
2
PDGFRL 8p22-p21.3 PDGRL, PRLTS -PDGFRL and Breast Cancer
2
CD200 3q13.2 MRC, MOX1, MOX2, OX-2 -CD200 and Breast Cancer
2
IL12B 5q33.3 CLMF, NKSF, CLMF2, IMD28, IMD29, NKSF2, IL-12B -IL12B and Breast Cancer
2
ELK4 1q32 SAP1 -ELK4 and Breast Cancer
2
TM4SF1 3q21-q25 L6, H-L6, M3S1, TAAL6 -TM4SF1 and Breast Cancer
2
FSTL3 19p13 FLRG, FSRP -FSTL3 and Breast Cancer
2
ZNF331 19q13.42 RITA, ZNF361, ZNF463 -ZNF331 and Breast Cancer
2
KAT6B 10q22.2 qkf, MORF, MOZ2, GTPTS, MYST4, ZC2HC6B, querkopf -KAT6B and Breast Cancer
1
CRTC3 15q26.1 TORC3, TORC-3 -CRTC3 and Breast Cancer
1
PRTN3 19p13.3 MBN, MBT, NP4, P29, PR3, ACPA, AGP7, NP-4, PR-3, CANCA, C-ANCA -PRTN3 and Breast Cancer
1
PLCD1 3p22-p21.3 NDNC3, PLC-III -PLCD1 and Breast Cancer
1
GPRC6A 6q22.1 GPCR, bA86F4.3 -GPRC6A and Breast Cancer
1
COX6C 8q22.2 -COX6C and Breast Cancer
1
TRG 7p14 TCRG, TRG@ -TRG and Breast Cancer
1
EIF4A2 3q28 DDX2B, EIF4A, EIF4F, BM-010, eIF4A-II, eIF-4A-II -EIF4A2 and Breast Cancer
1
PNN 14q21.1 DRS, DRSP, SDK3, memA -PNN and Breast Cancer
1
SRGAP3 3p25.3 WRP, MEGAP, SRGAP2, ARHGAP14 -SRGAP3 and Breast Cancer
1
S100A3 1q21 S100E -S100A3 and Breast Cancer
1
ARHGEF12 11q23.3 LARG, PRO2792 -ARHGEF12 and Breast Cancer
1
KMT2D 12q13.12 ALR, KMS, MLL2, MLL4, AAD10, KABUK1, TNRC21, CAGL114 -KMT2D and Breast Cancer
1
ETV3 1q21-q23 PE1, METS, PE-1, bA110J1.4 -ETV3 and Breast Cancer
1
ARHGEF5 7q35 P60, TIM, GEF5, TIM1 -ARHGEF5 and Breast Cancer
1
ERC1 12p13.3 ELKS, Cast2, ERC-1, RAB6IP2 -ERC1 and Breast Cancer
1
CTNND1 11q11 CAS, p120, CTNND, P120CAS, P120CTN, p120(CAS), p120(CTN) -CTNND1 and Breast Cancer
1
EXTL1 1p36.1 EXTL -EXTL1 and Breast Cancer
1
SMAD7 18q21.1 CRCS3, MADH7, MADH8 -SMAD7 and Breast Cancer
HOXC10 12q13.3 HOX3I Epigenetics
-HOXC10 Silencing in ER positive Breast Cancer

Note: list is not exhaustive. Number of papers are based on searches of PubMed (click on topic title for arbitrary criteria used).

Latest Publications

Wang CH, Gao XJ, Liao SY, et al.
[Transcriptome analysis of human breast cancer cell lines MCF-7 and MDA-MB- 435 by RNA-seq].
Mol Biol (Mosk). 2015 Mar-Apr; 49(2):279-88 [PubMed] Related Publications
The transcriptomic profiles of human breast cancer cell lines MCF-7 and MDA-MB-435 were investigated using the next-generation RNA sequencing (RNA-Seq). The DESeq package was used to screen the differentially expressed transcripts. A total of 229 genes with a significantly differential expression in MDA-MB-435 cells as compared with MCF-7 cells were obtained. Annotation of the biological functions of these genes through the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.7 demonstrated that the 229 differentially expressed genes were mainly implicated in the biological functions related to cell adhesion and motion, antigen processing and presentation (via MHC class II), hormone response, extracellular structure organization, tissue remodeling, and cell proliferation regulation. Analysis of the individual genes demonstrated that MDA-MB-435 cells exhibited a higher tendency to metastasis and antigen processing and presentation, and lower ability to hormone response. Twenty most abundant transcripts in MDA-MB-435 cells, such as VIM, TNC, and CD74, represent its high potential for metastasis. Besides the genes previously reported to be involved in tumor metastasis and development, genes newly identified in this study could provide new clues for the diagnosis and prognosis of aggressive breast cancers.

Yamamoto-Ibusuki M, Arnedos M, André F
Targeted therapies for ER+/HER2- metastatic breast cancer.
BMC Med. 2015; 13:137 [PubMed] Free Access to Full Article Related Publications
The majority of breast cancers present with estrogen receptor (ER)-positive and human epidermal growth factor receptor (HER2)-negative features and might benefit from endocrine therapy. Although endocrine therapy has notably evolved during the last decades, the invariable appearance of endocrine resistance, either primary or secondary, remains an important issue in this type of tumor. The improvement of our understanding of the cancer genome has identified some promising targets that might be responsible or linked to endocrine resistance, including alterations affecting main signaling pathways like PI3K/Akt/mTOR and CCND1/CDK4-6 as well as the identification of new ESR1 somatic mutations, leading to an array of new targeted therapies that might circumvent or prevent endocrine resistance. In this review, we have summarized the main targeted therapies that are currently being tested in ER+ breast cancer, the rationale behind them, and the new agents and combinational treatments to come.

Tsui T, Miller WT
Cancer-Associated Mutations in Breast Tumor Kinase/PTK6 Differentially Affect Enzyme Activity and Substrate Recognition.
Biochemistry. 2015; 54(20):3173-82 [PubMed] Related Publications
Brk (breast tumor kinase, also known as PTK6) is a nonreceptor tyrosine kinase that is aberrantly expressed in several cancers and promotes cell proliferation and transformation. Genome sequencing studies have revealed a number of cancer-associated somatic mutations in the Brk gene; however, their effect on Brk activity has not been examined. We analyzed a panel of cancer-associated mutations and determined that several of the mutations activate Brk, while two eliminated enzymatic activity. Three of the mutations (L16F, R131L, and P450L) are located in important regulatory domains of Brk (the SH3, SH2 domains, and C-terminal tail, respectively). Biochemical data suggest that they activate Brk by disrupting intramolecular interactions that normally maintain Brk in an autoinhibited conformation. We also observed differential effects on recognition and phosphorylation of substrates, suggesting that the mutations can influence downstream Brk signaling by multiple mechanisms.

Ross JS, Badve S, Wang K, et al.
Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.
Arch Pathol Lab Med. 2015; 139(5):642-9 [PubMed] Related Publications
CONTEXT: Metastatic metaplastic breast carcinoma (MPBC) is an uncommon, but aggressive, tumor resistant to conventional chemotherapy.
OBJECTIVE: To learn whether next-generation sequencing could identify potential targets of therapy for patients with relapsed and metastatic MPBC.
DESIGN: Hybridization capture of 3769 exons from 236 cancer-related genes and 47 introns of 19 genes commonly rearranged in cancer was applied to a minimum of 50 ng of DNA extracted from 20 MPBC formalin-fixed, paraffin-embedded specimens and sequenced to high uniform coverage.
RESULTS: The 20 patients with MPBC had a median age of 62 years (range, 42-86 years). There were 9 squamous (45%), 9 chondroid (45%), and 2 spindle cell (10%) MPBCs, all of which were high grade. Ninety-three genomic alterations were identified, (range, 1-11) with 19 of the 20 cases (95%) harboring an alteration that could potentially lead to a targeted treatment option. The most-common alterations were in TP53 (n = 69; 75%), PIK3CA (n = 37; 40%), MYC (n = 28; 30%), MLL2 (n = 28; 30%), PTEN (n = 23; 25%), CDKN2A/B (n = 19; 20%), CCND3 (n = 14; 15%), CCNE1 (n = 9; 10%), EGFR (n = 9; 10%), and KDM6A (n = 9; 10%); AKT3, CCND1, CCND2, CDK4, FBXW7, FGFR1, HRAS, NF1, PIK3R1, and SRC were each altered in a single case. All 16 MPBCs (100%) that were negative for ERBB2 (HER2) overexpression by immunohistochemistry and/or ERBB2 (HER2) amplification by fluorescence in situ hybridization were also uniformly (100%) negative for ERBB2 amplification by next-generation sequencing-based copy-number assessment.
CONCLUSIONS: Our results indicate that genomic profiling using next-generation sequencing can identify clinically meaningful alterations that have the potential to guide targeted treatment decisions in most patients with metastatic MPBC.

Arcand SL, Akbari MR, Mes-Masson AM, et al.
Germline TP53 mutational spectrum in French Canadians with breast cancer.
BMC Med Genet. 2015; 16:24 [PubMed] Free Access to Full Article Related Publications
BACKGROUND: Specific germline mutations in the hereditary breast-ovarian cancer susceptibility (HBC/HBOC) genes, BRCA1, BRCA2 and PALB2, have been shown to recur in French Canadians of Quebec, Canada, and this has been attributed to common ancestors. Germline TP53 mutation carriers are known to segregate in Li-Fraumeni syndrome families, which feature young age of onset breast cancer. We have reported rare TP53 mutation carriers in French Canadian HBC families, though none recurred possibly due to the limited number of cancer families investigated. Here we describe TP53 germline mutations found in French Canadian cancer families provided from hereditary cancer clinics; investigate 37 new BRCA1 and BRCA2 mutation-negative HBC/HBOC families for the TP53 mutations; and assess the frequency of TP53 mutations in a 1235 French Canadian breast cancer cases not selected for family history of cancer.
METHODS: TP53 mutation-positive pedigrees from French Canadian cancer families were provided from local hereditary cancer clinics. Bidirectional Sanger sequencing of all protein encoding exons of TP53 was performed using peripheral blood lymphocyte DNA from breast/ovarian cancer probands from 37 HBC/HBOC families of French Canadian descent. Targeted bidirectional Sanger sequencing assay of regions containing the identified TP53 mutations was performed on 1235 French Canadian breast cancer cases not selected for family history cancer.
RESULTS: Five new TP53 mutations were identified in six pedigrees from hereditary cancer clinics. No deleterious mutations were identified in cancer probands from 37 HBC/HBOC families. A targeted mutation screen of the 1235 breast cancer cases identified a c.844C>T [p.Arg282Trp] mutation carrier. This mutation was also found among the six mutation-positive cancer families provided by the local hereditary cancer clinics. The targeted screen also uncovered a new TP53 mutation, c.685T>C [p.Cys229Arg] that was found in two breast cancer cases. All TP53 mutation carriers were among the 656 women with breast cancer diagnosed less than 50 years of age.
CONCLUSIONS: In all six new TP53 mutations were identified in French Canadians, where two each occurred in independently ascertained cases/families. Although all newly identified breast cancer mutation carriers reported a family history of cancer, none were consistent with features of Li-Fraumeni syndrome families.

Guo Q, Schmidt MK, Kraft P, et al.
Identification of novel genetic markers of breast cancer survival.
J Natl Cancer Inst. 2015; 107(5) [PubMed] Related Publications
BACKGROUND: Survival after a diagnosis of breast cancer varies considerably between patients, and some of this variation may be because of germline genetic variation. We aimed to identify genetic markers associated with breast cancer-specific survival.
METHODS: We conducted a large meta-analysis of studies in populations of European ancestry, including 37954 patients with 2900 deaths from breast cancer. Each study had been genotyped for between 200000 and 900000 single nucleotide polymorphisms (SNPs) across the genome; genotypes for nine million common variants were imputed using a common reference panel from the 1000 Genomes Project. We also carried out subtype-specific analyses based on 6881 estrogen receptor (ER)-negative patients (920 events) and 23059 ER-positive patients (1333 events). All statistical tests were two-sided.
RESULTS: We identified one new locus (rs2059614 at 11q24.2) associated with survival in ER-negative breast cancer cases (hazard ratio [HR] = 1.95, 95% confidence interval [CI] = 1.55 to 2.47, P = 1.91 x 10(-8)). Genotyping a subset of 2113 case patients, of which 300 were ER negative, provided supporting evidence for the quality of the imputation. The association in this set of case patients was stronger for the observed genotypes than for the imputed genotypes. A second locus (rs148760487 at 2q24.2) was associated at genome-wide statistical significance in initial analyses; the association was similar in ER-positive and ER-negative case patients. Here the results of genotyping suggested that the finding was less robust.
CONCLUSIONS: This is currently the largest study investigating genetic variation associated with breast cancer survival. Our results have potential clinical implications, as they confirm that germline genotype can provide prognostic information in addition to standard tumor prognostic factors.

Terrenato I, Pennacchia I, Buglioni S, et al.
HER2 status determination: analyzing the problems to find the solutions.
Medicine (Baltimore). 2015; 94(15):e645 [PubMed] Related Publications
Misdiagnosis in the evaluation of HER2 status in breast cancer may have consequent negative impact on clinical decision-making. Therefore, it has become ever more important to share procedures and interpretation criteria for HER2 testing among laboratories. Herein, we report an interlaboratory survey among 9 hospitals located in the central-south regions of Italy. The centers sent a series of 36 slides, 4 for each HER2 score, to the revising centers. We found a good concordance in HER2 scoring for 0 and 3+ score, but a very low concordance for 1+ and 2+ scores. To focus on factors that may lead to discordant results, we report 4 cases which summarized the most common source of discrepancy in HER2 testing. This methodological approach will help the individual laboratory to minimize technical variables and to reduce the percentage of erroneous interpretations of HER2 status.

Fitzal F, Filipits M, Rudas M, et al.
The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.
Br J Cancer. 2015; 112(8):1405-10 [PubMed] Article available free on PMC after 14/04/2016 Related Publications
BACKGROUND: The aim of this study was to examine whether EndoPredict (EP), a novel genomic expression test, is effective in predicting local recurrence (LR)-free survival (LRFS) following surgery for breast cancer in postmenopausal women. In addition, we examined whether EP may help tailor local therapy in these patients.
METHODS: From January 1996 to June 2004, 3714 postmenopausal patients were randomly assigned to either tamoxifen or tamoxifen followed by anastrozole within the prospective ABCSG 8 trial. Using assay scores from EP, we classified breast tumour blocks as either low or high risk for recurrence.
RESULTS: Data were gathered from 1324 patients. The median follow-up was 72.3 months and the cumulative incidence of LR was 2.6% (0.4% per year). The risk of LR over a 10-year period among patients with high-risk lesions (n=683) was significantly higher (LRFS=91%) when compared with patients with low-risk lesions (n=641) (10-year LRFS=97.5%) (HR: 1.31 (1.16-1.48) P<0.005). The groups that received breast conservation surgery (BCT) and mastectomy (MX) had similar LR rates (P=0.879). Radiotherapy (RT) after BCT significantly improved LRFS in the cohorts predicted by EP to be low-risk for LR (received RT: n=436, 10-year LRFS 99.8%; did not receive RT: n=63, 10-year LRFS 83.6%, P<0.005).
CONCLUSIONS: EndoPredict is an effective prognostic tool for predicting LRFS. Among postmenopausal, low-risk patients, EP does not appear to be useful for tailoring local therapy.

Mavaddat N, Pharoah PD, Michailidou K, et al.
Prediction of breast cancer risk based on profiling with common genetic variants.
J Natl Cancer Inst. 2015; 107(5) [PubMed] Related Publications
BACKGROUND: Data for multiple common susceptibility alleles for breast cancer may be combined to identify women at different levels of breast cancer risk. Such stratification could guide preventive and screening strategies. However, empirical evidence for genetic risk stratification is lacking.
METHODS: We investigated the value of using 77 breast cancer-associated single nucleotide polymorphisms (SNPs) for risk stratification, in a study of 33 673 breast cancer cases and 33 381 control women of European origin. We tested all possible pair-wise multiplicative interactions and constructed a 77-SNP polygenic risk score (PRS) for breast cancer overall and by estrogen receptor (ER) status. Absolute risks of breast cancer by PRS were derived from relative risk estimates and UK incidence and mortality rates.
RESULTS: There was no strong evidence for departure from a multiplicative model for any SNP pair. Women in the highest 1% of the PRS had a three-fold increased risk of developing breast cancer compared with women in the middle quintile (odds ratio [OR] = 3.36, 95% confidence interval [CI] = 2.95 to 3.83). The ORs for ER-positive and ER-negative disease were 3.73 (95% CI = 3.24 to 4.30) and 2.80 (95% CI = 2.26 to 3.46), respectively. Lifetime risk of breast cancer for women in the lowest and highest quintiles of the PRS were 5.2% and 16.6% for a woman without family history, and 8.6% and 24.4% for a woman with a first-degree family history of breast cancer.
CONCLUSIONS: The PRS stratifies breast cancer risk in women both with and without a family history of breast cancer. The observed level of risk discrimination could inform targeted screening and prevention strategies. Further discrimination may be achievable through combining the PRS with lifestyle/environmental factors, although these were not considered in this report.

Nasedkina TV, Gromyko OE, Emel'ianova MA, et al.
[Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips].
Mol Biol (Mosk). 2014 Mar-Apr; 48(2):243-50 [PubMed] Related Publications
Germline mutations of BRCA1/2 genes cause the predisposition of their carriers to breast or/and ovary cancers (BC or/and OC) during the lifetime. Identification of these mutations is a basis of molecular diagnosis for BC susceptibility. Rapid genotyping technique using microarrays for identification of BRCA1 185delAG, 300T>G, 4153delA, 5382insC mutations and 4158 A>G sequence variant; BRCA2 695insT and 6174delT mutations; 1100delC mutation in CHEK2 gene was applied for 412 randomly collected breast cancer samples from the central region of European area of Russia. In 25 (6.0%) patients (6.0%) BC was associated with other tumours: OC, cervical cancer, colorectal cancer etc. BRCA1/2 and CHEK2 mutations were found in 33 (8.0%) BC patients. The most frequent mutation was BRCA1 5382insC, occurred in 16 (3.9%) BC patients, and CHEK2 1100delC, revealed in 7 (1.7%) BC patients. An application of diagnostic BC-microarray for genetic testing of BRCA1/2 and CHEK2 founder mutations has been discussed.

Rebbeck TR, Mitra N, Wan F, et al.
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
JAMA. 2015; 313(13):1347-61 [PubMed] Related Publications
IMPORTANCE: Limited information about the relationship between specific mutations in BRCA1 or BRCA2 (BRCA1/2) and cancer risk exists.
OBJECTIVE: To identify mutation-specific cancer risks for carriers of BRCA1/2.
DESIGN, SETTING, AND PARTICIPANTS: Observational study of women who were ascertained between 1937 and 2011 (median, 1999) and found to carry disease-associated BRCA1 or BRCA2 mutations. The international sample comprised 19,581 carriers of BRCA1 mutations and 11,900 carriers of BRCA2 mutations from 55 centers in 33 countries on 6 continents. We estimated hazard ratios for breast and ovarian cancer based on mutation type, function, and nucleotide position. We also estimated RHR, the ratio of breast vs ovarian cancer hazard ratios. A value of RHR greater than 1 indicated elevated breast cancer risk; a value of RHR less than 1 indicated elevated ovarian cancer risk.
EXPOSURES: Mutations of BRCA1 or BRCA2.
MAIN OUTCOMES AND MEASURES: Breast and ovarian cancer risks.
RESULTS: Among BRCA1 mutation carriers, 9052 women (46%) were diagnosed with breast cancer, 2317 (12%) with ovarian cancer, 1041 (5%) with breast and ovarian cancer, and 7171 (37%) without cancer. Among BRCA2 mutation carriers, 6180 women (52%) were diagnosed with breast cancer, 682 (6%) with ovarian cancer, 272 (2%) with breast and ovarian cancer, and 4766 (40%) without cancer. In BRCA1, we identified 3 breast cancer cluster regions (BCCRs) located at c.179 to c.505 (BCCR1; RHR = 1.46; 95% CI, 1.22-1.74; P = 2 × 10(-6)), c.4328 to c.4945 (BCCR2; RHR = 1.34; 95% CI, 1.01-1.78; P = .04), and c. 5261 to c.5563 (BCCR2', RHR = 1.38; 95% CI, 1.22-1.55; P = 6 × 10(-9)). We also identified an ovarian cancer cluster region (OCCR) from c.1380 to c.4062 (approximately exon 11) with RHR = 0.62 (95% CI, 0.56-0.70; P = 9 × 10(-17)). In BRCA2, we observed multiple BCCRs spanning c.1 to c.596 (BCCR1; RHR = 1.71; 95% CI, 1.06-2.78; P = .03), c.772 to c.1806 (BCCR1'; RHR = 1.63; 95% CI, 1.10-2.40; P = .01), and c.7394 to c.8904 (BCCR2; RHR = 2.31; 95% CI, 1.69-3.16; P = .00002). We also identified 3 OCCRs: the first (OCCR1) spanned c.3249 to c.5681 that was adjacent to c.5946delT (6174delT; RHR = 0.51; 95% CI, 0.44-0.60; P = 6 × 10(-17)). The second OCCR spanned c.6645 to c.7471 (OCCR2; RHR = 0.57; 95% CI, 0.41-0.80; P = .001). Mutations conferring nonsense-mediated decay were associated with differential breast or ovarian cancer risks and an earlier age of breast cancer diagnosis for both BRCA1 and BRCA2 mutation carriers.
CONCLUSIONS AND RELEVANCE: Breast and ovarian cancer risks varied by type and location of BRCA1/2 mutations. With appropriate validation, these data may have implications for risk assessment and cancer prevention decision making for carriers of BRCA1 and BRCA2 mutations.

Jagsi R, Griffith KA, Kurian AW, et al.
Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer.
J Clin Oncol. 2015; 33(14):1584-91 [PubMed] Article available free on PMC after 10/05/2016 Related Publications
PURPOSE: To evaluate preferences for and experiences with genetic testing in a diverse cohort of patients with breast cancer identified through population-based registries, with attention to differences by race/ethnicity.
METHODS: We surveyed women diagnosed with nonmetastatic breast cancer from 2005 to 2007, as reported to the SEER registries of metropolitan Los Angeles and Detroit, about experiences with hereditary risk evaluation. Multivariable models evaluated correlates of a strong desire for genetic testing, unmet need for discussion with a health care professional, and receipt of testing.
RESULTS: Among 1,536 patients who completed the survey, 35% expressed strong desire for genetic testing, 28% reported discussing testing with a health care professional, and 19% reported test receipt. Strong desire for testing was more common in younger women, Latinas, and those with family history. Minority patients were significantly more likely to have unmet need for discussion (failure to discuss genetic testing with a health professional when they had a strong desire for testing): odds ratios of 1.68, 2.44, and 7.39 for blacks, English-speaking Latinas, and Spanish-speaking Latinas compared with whites, respectively. Worry in the long-term survivorship period was higher among those with unmet need for discussion (48.7% v 24.9%; P <.001). Patients who received genetic testing were younger, less likely to be black, and more likely to have a family cancer history.
CONCLUSION: Many patients, especially minorities, express a strong desire for genetic testing and may benefit from discussion to clarify risks. Clinicians should discuss genetic risk even with patients they perceive to be at low risk, as this may reduce worry.

Jordan VC, Curpan R, Maximov PY
Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators.
J Natl Cancer Inst. 2015; 107(6):djv075 [PubMed] Related Publications
The consistent reports of mutations at Asp538 and Tyr537 in helix 12 of the ligand-binding domain (LBD) of estrogen receptors (ERs) from antihormone-resistant breast cancer metastases constitute an important advance. The mutant amino acids interact with an anchor amino acid, Asp351, to close the LBD, thereby creating a ligand-free constitutively activated ER. Amino acids Asp 538, Tyr 537, and Asp 351 are known to play a role in either the turnover of ER, the antiestrogenic activity of the ER complex, or the estrogen-like actions of selective ER modulators. A unifying mechanism of action for these amino acids to enhance ER gene activation and growth response is presented. There is a range of mutations described in metastases vs low to zero in primary disease, so the new knowledge is of clinical relevance, thereby confirming an additional mechanism of acquired resistance to antihormone therapy through cell population selection pressure and enrichment during treatment. Circulating tumor cells containing ER mutations can be cultured ex vivo, and tumor tissues can be grown as patient-derived xenografts to add a new dimension for testing drug susceptibility for future drug discovery.

Wang L, Zhang W, Lyu S, et al.
Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast.
Tumour Biol. 2015; 36(4):2241-8 [PubMed] Related Publications
Patients with microinvasive carcinoma often have favorable prognosis, but it remains unclear whether this special type of breast cancer represents a distinct morphological entity with its own biological features and clinical behavior distinct from those of ductal carcinoma in situ (DCIS). The study is a retrospective analysis of a large patient cohort from a single institution. One hundred and thirty one microinvasive carcinoma and 451 DCIS cases were collected. ER, PR, HER2, and Ki67 were examined by immunohistochemistry in pathological sections. We assessed the clinicopathologic characteristics, molecular features, and survival status of microinvasive carcinoma and compared to those of DCIS. Microinvasive carcinoma differed from DCIS with respect to tumor size, lymph node status, and initial presentation (P < 0.05). There was a significant difference in nuclear grade among microinvasive carcinoma of different molecular subtype (P < 0.05). The clinicalpathologic features and outcomes of patients with microinvasive carcinoma were similar to those with DCIS. The 5-year OS rate for microinvasive carcinoma and DCIS patients was 99.0 and 99.2%, respectively. A combination of pathologic, clinical, and molecular factors may ultimately reveal more powerful and robust measures for disease classification than any one modality alone. Microinvasive carcinoma does not significantly predict for worse DFS or OS in comparison with patients with DCIS.

Onstenk W, Sieuwerts AM, Weekhout M, et al.
Gene expression profiles of circulating tumor cells versus primary tumors in metastatic breast cancer.
Cancer Lett. 2015; 362(1):36-44 [PubMed] Related Publications
Before using circulating tumor cells (CTCs) as liquid biopsy, insight into molecular discrepancies between CTCs and primary tumors is essential. We characterized CellSearch-enriched CTCs from 62 metastatic breast cancer (MBC) patients with ≥5 CTCs starting first-line systemic treatment. Expression levels of 35 tumor-associated, CTC-specific genes, including ESR1, coding for the estrogen receptor (ER), were measured by reverse transcription quantitative polymerase chain reaction and correlated to corresponding primary tumors. In 30 patients (48%), gene expression profiles of 35 genes were discrepant between CTCs and the primary tumor, but this had no prognostic consequences. In 15 patients (24%), the expression of ER was discrepant. Patients with ER-negative primary tumors and ER-positive CTCs had a longer median TTS compared to those with concordantly ER-negative CTCs (8.5 versus 2.1 months, P = 0.05). From seven patients, an axillary lymph node metastasis was available. In two patients, the CTC profiles better resembled the lymph node metastasis than the primary tumor. Our findings suggest that molecular discordances between CTCs and primary tumors frequently occur, but that this bears no prognostic consequences. Alterations in ER-status between primary tumors and CTCs might have prognostic implications.

Wang Y, Yang H, Wang H
Note of clarification of data in the paper entitled association between BRIP1 (BACH1) polymorphisms and breast cancer risk.
Breast Cancer Res Treat. 2015; 150(3):467-71 [PubMed] Related Publications
With great interest, we read the recent article entitled "Association between BRIP1 (BACH1) polymorphisms and breast cancer risk: a meta-analysis" published online in Pabalan et al. (Breast Cancer Res Treat 137:553-558, 2013). This article suggests that overall summary estimates imply no associations but suggest susceptibility among carriers of the C47G polymorphism and Pro-Ser genotype in premenopausal women. The result is encouraging. Nevertheless, several key issues in this meta-analysis are worth noticing.

Zhang Z, Yang C, Gao W, et al.
FOXA2 attenuates the epithelial to mesenchymal transition by regulating the transcription of E-cadherin and ZEB2 in human breast cancer.
Cancer Lett. 2015; 361(2):240-50 [PubMed] Related Publications
The Forkhead Box A2 (FOXA2) transcription factor is required for embryonic development and for normal functions of multiple adult tissues, in which the maintained expression of FOXA2 is usually related to preventing the progression of malignant transformation. In this study, we found that FOXA2 prevented the epithelial to mesenchymal transition (EMT) in human breast cancer. We observed a strong correlation between the expression levels of FOXA2 and the epithelial phenotype. Knockdown of FOXA2 promoted the mesenchymal phenotype, whereas stable overexpression of FOXA2 attenuated EMT in breast cancer cells. FOXA2 was found to endogenously bind to and stimulate the promoter of E-cadherin that is crucial for epithelial phenotype of the tumor cells. Meanwhile, FOXA2 prevented EMT of breast cancer cells by repressing the expression of EMT-related transcription factor ZEB2 through recruiting a transcriptional corepressor TLE3 to the ZEB2 promoter. The stable overexpression of FOXA2 abolished metastasis of breast cancer cells in vivo. This study confirmed that FOXA2 inhibited EMT in breast cancer cells by regulating the transcription of EMT-related genes such as E-cadherin and ZEB2.

Papaconstantinou I, Mantzos DS, Asimakoula K, et al.
A 12-year experience at a tertiary hospital on patients with multiple primary malignant neoplasms.
J BUON. 2015 Jan-Feb; 20(1):332-7 [PubMed] Related Publications
PURPOSE: The incidence of multiple primary malignant neoplasms (MPMN) has dramatically increased. The purpose of this retrospective study was to present the 12-year experience at a University Hospital in patients with MPMN and to investigate the role of genetic factors in their pathogenesis.
METHODS: The medical records of 7516 cancer patients, treated in our Institution from 2000 to 2012, were reviewed. Diagnosis of MPMN was based on the Warren and Gates' criteria.
RESULTS: Among 7516 patients, 39 (0.5%) (10 men, mean age 70.0±6.98 years, and 29 women, mean age 64.7±8.24 years) presented with MPMN. Eighty-two percent of them developed 2 primary malignant neoplasms (PMNs), whereas 3 PMNs were developed in 7 patients. Breast cancer was the most common cancer type diagnosed among female patients (59%); 14 and 3 had 2 and 3 PMNs, respectively. Eight had a family history of breast cancer while in 3 genetic testing revealed mutations in BRCA1 and BRCA2 genes. The second most common type of malignancy was colorectal cancer (24%); 5 developed 2 PMNs, whereas 2 developed 3 PMNs. Five patients had a family history of colorectal cancer. Colon cancer was the most frequent neoplasm among male patients (50%; 3 developed 2 and 2 3 PMNs. In 2 patients the family history was positive for colorectal cancer.
CONCLUSIONS: Although many factors may contribute to MPMN development, positive family history and inherent mutations significantly predispose to MPMN appearance. Thus, management of MPMN patients should be based on a detailed family history and genetic testing.

van Roosmalen W, Le Dévédec SE, Golani O, et al.
Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant.
J Clin Invest. 2015; 125(4):1648-64 [PubMed] Article available free on PMC after 10/05/2016 Related Publications
Tumor cell migration is a key process for cancer cell dissemination and metastasis that is controlled by signal-mediated cytoskeletal and cell matrix adhesion remodeling. Using a phagokinetic track assay with migratory H1299 cells, we performed an siRNA screen of almost 1,500 genes encoding kinases/phosphatases and adhesome- and migration-related proteins to identify genes that affect tumor cell migration speed and persistence. Thirty candidate genes that altered cell migration were validated in live tumor cell migration assays. Eight were associated with metastasis-free survival in breast cancer patients, with integrin β3-binding protein (ITGB3BP), MAP3K8, NIMA-related kinase (NEK2), and SHC-transforming protein 1 (SHC1) being the most predictive. Examination of genes that modulate migration indicated that SRPK1, encoding the splicing factor kinase SRSF protein kinase 1, is relevant to breast cancer outcomes, as it was highly expressed in basal breast cancer. Furthermore, high SRPK1 expression correlated with poor breast cancer disease outcome and preferential metastasis to the lungs and brain. In 2 independent murine models of breast tumor metastasis, stable shRNA-based SRPK1 knockdown suppressed metastasis to distant organs, including lung, liver, and spleen, and inhibited focal adhesion reorganization. Our study provides comprehensive information on the molecular determinants of tumor cell migration and suggests that SRPK1 has potential as a drug target for limiting breast cancer metastasis.

Zhou J, Qian S, Li H, et al.
Predictive value of microtubule-associated protein Tau in patients with recurrent and metastatic breast cancer treated with taxane-containing palliative chemotherapy.
Tumour Biol. 2015; 36(5):3941-7 [PubMed] Related Publications
Tau is a member of microtubule-associated proteins (MAPs) and expressed in normal breast epithelium and breast cancer cells. Tau expression levels in early breast cancer were correlated with the responsiveness of taxane-containing chemotherapy. However, it is unknown whether Tau contributes to breast cancer progression. Herein, Tau expression in recurrent and metastatic breast cancer (RMBC) and its predictive significance in taxane-containing palliative chemotherapy were investigated. Immunohistochemical (IHC) staining was conducted to detect Tau protein expression levels in biopsies from 285 patients with RMBC, and the correlation between Tau expression and sensitivity to taxane was evaluated. One hundred twenty-one (42.46 %, 121/285) patients were Tau positive in their tumor. One hundred ninety-four (68.07 %, 194/285) patients were effective clinical remission, which evaluated with response evaluation criteria in solid tumors (RECIST) criteria. In this group, 141 (85.98 %, 141/194) patients were Tau negative. We further analyzed the correlation between Tau expression and clinicopathological characteristics. Tau expression was positively correlated to estrogen receptor (ER) status. Multivariate logistic regression analysis showed that Tau expression significantly differentiated patients with effective response to treatment (95 % confidence interval (CI): 4.230-13.88, P < 0.01). Tau expression was identified as an independent factor to predict the sensitivity of tumors to taxane-containing palliative chemotherapy in RMBC, suggesting that Tau expression in RMBC may serve as a clinical predictor for taxane-containing palliative chemotherapy.

Liu B, Sun L, Liu Q, et al.
A cytoplasmic NF-κB interacting long noncoding RNA blocks IκB phosphorylation and suppresses breast cancer metastasis.
Cancer Cell. 2015; 27(3):370-81 [PubMed] Related Publications
NF-κB is a critical link between inflammation and cancer, but whether long non-coding RNAs (lncRNAs) regulate its activation remains unknown. Here, we identify an NF-KappaB Interacting LncRNA (NKILA), which is upregulated by NF-κB, binds to NF-κB/IκB, and directly masks phosphorylation motifs of IκB, thereby inhibiting IKK-induced IκB phosphorylation and NF-κB activation. Unlike DNA that is dissociated from NF-κB by IκB, NKILA interacts with NF-κB/IκB to form a stable complex. Importantly, NKILA is essential to prevent over-activation of NF-κB pathway in inflammation-stimulated breast epithelial cells. Furthermore, low NKILA expression is associated with breast cancer metastasis and poor patient prognosis. Therefore, lncRNAs can directly interact with functional domains of signaling proteins, serving as a class of NF-κB modulators to suppress cancer metastasis.

Clergue O, Jones N, Sévenet N, et al.
[Should knowledge of BRCA1 status impact the choice of chemotherapy in metastatic breast cancer: a review].
Bull Cancer. 2015; 102(3):245-55 [PubMed] Related Publications
BRCA1 and BRCA2 mutations account for 40% of cancer predisposition gene mutations identified in the current French diagnostic setting. The proteins encoded by these genes are implicated in DNA repair pathways. As a result, loss of BRCA1 or BRCA2 function may modify chemo-sensitivity. This literature review aims to determine whether BRCA1 mutation status should influence the choice of systemic treatment in breast cancer. Fourteen articles and four abstracts from 12 retrospective analyses and 6 prospective studies were identified in the literature review. CMF-type and taxane-based protocols appear to be insufficiently effective, while anthracycline activity does not seem to be affected by BRCA1 status. BRCA1-mutated tumours appear to be highly sensitive to platinum, in both the neoadjuvant and metastatic setting. Olaparib, a PARP inhibitor, has only been evaluated in one study in metastatic patients, with promising results. The presence of a BRCA1 mutation can lead to an adaptation of therapies in the metastatic stages in breast cancer. The rapid identification of BRCA1 mutations and the adaptation of treatment according to this status in the (neo)adjuvant setting is likely to become a reality in the coming years.

Chou WY, Chuang KH, Sun D, et al.
Inhibition of PKC-Induced COX-2 and IL-8 Expression in Human Breast Cancer Cells by Glucosamine.
J Cell Physiol. 2015; 230(9):2240-51 [PubMed] Related Publications
Breast cancer is a common cancer leading to many deaths among females. Cyclooxygenase-2 (COX-2) and interleukin-8 (IL-8) are two highly expressed inflammatory mediators to be induced by the protein kinase C (PKC) signaling via various inflammatory stimuli and both contribute significantly to cancer metastasis/progression. Glucosamine has been shown to act as an anti-inflammation molecule. The aim of this study was to clarify the role and acting mechanism of glucosamine during the PKC-regulation of COX-2/IL-8 expression and the associated impact on breast cancer. In MCF-7 breast cancer cells, glucosamine effectively suppresses the PKC induction of COX-2 and IL-8 promoter activity, mRNA and protein levels, as well as the production of prostaglandin E(2) (PGE(2)) and IL-8. Glucosamine is able to promote COX-2 protein degradation in a calpain-dependent manner and IL-8 protein degradation in calpain-dependent and proteasome-dependent manners. The MAPK and NF-κB pathways are involved in PKC-induced COX-2 expression, but only the NF-κB pathway is involved in PKC-induced IL-8 expression. Glucosamine attenuates PKC-mediated IκBα phosphorylation, nuclear NF-κB translocation, and NF-κB reporter activation. Both PGE(2) and IL-8 promote cell proliferation and IL-8 induces cell migration; thus, glucosamine appears to suppress PKC-induced cell proliferation and migration. Furthermore, glucosamine significantly inhibits the growth of breast cancer xenografts and this is accompanied by a reduction in COX-2 and IL-8 expression. In conclusion, glucosamine seems to attenuate the inflammatory response in vitro and in vivo and this occurs, at least in part by targeting to the NF-κB signaling pathway, resulting in an inhibition of breast cancer cell growth.

Michailidou K, Beesley J, Lindstrom S, et al.
Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer.
Nat Genet. 2015; 47(4):373-80 [PubMed] Related Publications
Genome-wide association studies (GWAS) and large-scale replication studies have identified common variants in 79 loci associated with breast cancer, explaining ∼14% of the familial risk of the disease. To identify new susceptibility loci, we performed a meta-analysis of 11 GWAS, comprising 15,748 breast cancer cases and 18,084 controls together with 46,785 cases and 42,892 controls from 41 studies genotyped on a 211,155-marker custom array (iCOGS). Analyses were restricted to women of European ancestry. We generated genotypes for more than 11 million SNPs by imputation using the 1000 Genomes Project reference panel, and we identified 15 new loci associated with breast cancer at P < 5 × 10(-8). Combining association analysis with ChIP-seq chromatin binding data in mammary cell lines and ChIA-PET chromatin interaction data from ENCODE, we identified likely target genes in two regions: SETBP1 at 18q12.3 and RNF115 and PDZK1 at 1q21.1. One association appears to be driven by an amino acid substitution encoded in EXO1.

Arfaoui A, Douik H, Kablouti G, et al.
Role of p53 Codon72 SNP in breast cancer risk and anthracycline resistance.
Anticancer Res. 2015; 35(3):1763-9 [PubMed] Related Publications
BACKGROUND/AIM: We undertook a case-control and a case-case study to examine the possible association of p53 codon72 polymorphism with the breast cancer risk and resistance to anthracycline-based chemotherapy.
PATIENTS AND METHODS: Case-control study: This study enrolled 175 patients with breast cancer treated at the Salah Aziez Institute and 159 healthy Tunisian women (matched for age, ethnicity and origin), used as a control, with no clinical evidence of any neoplastic disorder. Case-Case study: 400 breast cancer patients, with invasive ductal carcinoma (IDC) treated with anthracycline based-chemotherapy. Genomic DNA was isolated from whole-blood leucocytes using the phenol-chloroform method. Anthracycline response was scored according to the World Health Organization (WHO) criteria. P53 codon72 polymorphism was genotyped using real-time polymerase chain reaction (RT-PCR) with the TaqMan method. Data were statistically analyzed using the Chi-square test.
RESULTS: Clinical data revealed that among the 400 patients, one quarter was resistant to chemotherapy treatment. Genetic data revealed that the p53 Arg72Pro genotype was found to be greatly associated with breast cancer risk (p<0.001), as well as tumor site (p=0.046). However, resistance to anthracycline-based chemotherapy does not seem to be correlated with p53 codon72 polymorphism in our population. Also, the distribution of tumor size, lymph node involvement and tumor grade was not significantly different among the polymorphic variants.
CONCLUSION: We conclude that p53 codon72 polymorphism is involved in susceptibility to developing breast cancer. It may be a factor of progression when breast sites are taken into account. However, there is no evidence indicating that Arg72Pro SNP may influence response to anthracycline-based chemotherapy.

Sui X, Wang X, Han W, et al.
MicroRNAs-mediated cell fate in triple negative breast cancers.
Cancer Lett. 2015; 361(1):8-12 [PubMed] Related Publications
MicroRNAs (miRNAs) are small non-coding RNAs that function as major modulators of posttranscriptional protein-coding gene expression in diverse biological processes including cell survival, cell cycle arrest, senescence, autophagy, and differentiation. The control of miRNAs plays an important role in cancer initiation and metastasis. Triple negative breast cancer (TNBC) is a distinct breast cancer subtype, which is defined by the absence of estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2/neu). Due to its high recurrence rate and poor prognosis, TNBC represents a challenge for breast cancer therapy. In recent years, a large number of microRNAs have been identified to play a crucial role in TNBC and some of them were found to be correlated with worse prognosis of TNBC. Thus, understanding the novel function of miRNAs may allow us to develop promising therapeutic targets for the treatment of TNBC patients.

Wang T, Liu JH, Zhang J, et al.
A multiplex allele-specific real-time PCR assay for screening of ESR1 mutations in metastatic breast cancer.
Exp Mol Pathol. 2015; 98(2):152-7 [PubMed] Related Publications
BACKGROUND: Acquired resistance to endocrine-based therapies occurs in virtually all estrogen receptor-α (ERα, encoded by ESR1) positive breast cancer patients. The underlying molecular mechanism is attributed to the activating mutations in ESR1. These mutations provide an exciting opportunity for the development of new antagonists that specifically inhibit the mutant proteins. Therefore, accurate detection of ESR1 mutations is of critical importance in clinical practice.
MATERIALS AND METHODS: We carried out a single tube, multiplex allele-specific real-time PCR assay for the detection of four ESR1 mutations (Y537S, Y537C, Y537N, and D538G).
RESULTS: The assay was found to be highly specific and sensitive. With this assay, as low as 1% mutant DNA template in wild type DNA could be detected. Fifteen DNA samples were prepared from archived formalin-fixed paraffin-embedded metastatic breast cancer biopsies. They were further screened with this assay, and three samples were identified as ESR1 mutant. The results were validated with pyrosequencing and complete concordance was observed between the two assays.
CONCLUSION: The multiplex allele-specific real-time PCR assay provides a rapid and reliable diagnostic tool for accurate detection of ESR1 mutations. This procedure may be used in the clinical treatment of breast cancer.

Vachon CM, Pankratz VS, Scott CG, et al.
The contributions of breast density and common genetic variation to breast cancer risk.
J Natl Cancer Inst. 2015; 107(5) [PubMed] Related Publications
We evaluated whether a 76-locus polygenic risk score (PRS) and Breast Imaging Reporting and Data System (BI-RADS) breast density were independent risk factors within three studies (1643 case patients, 2397 control patients) using logistic regression models. We incorporated the PRS odds ratio (OR) into the Breast Cancer Surveillance Consortium (BCSC) risk-prediction model while accounting for its attributable risk and compared five-year absolute risk predictions between models using area under the curve (AUC) statistics. All statistical tests were two-sided. BI-RADS density and PRS were independent risk factors across all three studies (P interaction = .23). Relative to those with scattered fibroglandular densities and average PRS (2(nd) quartile), women with extreme density and highest quartile PRS had 2.7-fold (95% confidence interval [CI] = 1.74 to 4.12) increased risk, while those with low density and PRS had reduced risk (OR = 0.30, 95% CI = 0.18 to 0.51). PRS added independent information (P < .001) to the BCSC model and improved discriminatory accuracy from AUC = 0.66 to AUC = 0.69. Although the BCSC-PRS model was well calibrated in case-control data, independent cohort data are needed to test calibration in the general population.

Yu H, Yang J, Li Y, Jiao S
[The expression of fibroblast activation protein-α in primary breast cancer is associated with poor prognosis].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015; 31(3):370-4 [PubMed] Related Publications
OBJECTIVE: To evaluate the prognostic value of fibroblast activation protein-α (FAP-α) expression in primary lesions of breast cancer patients and the relationship with the clinicopathologic features.
METHODS: Paraffin sections and clinical data were retrospectively collected from 130 stage I-III breast cancer patients who had underwent surgery at the Chinese PLA General Hospital from January 1st, 2000 to December 31st, 2002. Immunohistochemistry was used to assess FAP-α expression in primary lesions of breast cancer to evaluate the associations of FAP-α expression with transforming growth factor-β1 (TGF-β1) expression in breast cancer and patients' clinicopathologic characteristics and prognosis.
RESULTS: FAP-α was seen in cytoplasm of tumor cells and interstitial fibroblasts. Density of interstitial FAP-α-positive fibroblasts was positively correlated with the staining density of interstitial TGF-β-positive cells. Intensity of CTLA-4 expression in tumor cells was positively correlated with TGF-β1 expression in tumor cells. In patients whose lesions were negative for both estrogen and progesterone receptors, density of interstitial FAP-α-positive fibroblasts was an independent adverse prognostic factor for disease-free survival (DFS) and overall survival (OS); intensity of CTLA-4 expression in tumor cells was an independent adverse prognostic factor for DFS and OS.
CONCLUSION: High expression of FAP-α in primary breast tumors is associated with a bad prognosis in patients whose lesions are negative for both estrogen and progesterone receptors. Expression of TGF-β1 is positively related with FAP-α expression in primary breast tumors.

Pang X, Li K, Wei L, et al.
[IL-8 inhibits the apoptosis of MCF-7 human breast cancer cells by up-regulating Bcl-2 and down-regulating caspase-3].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015; 31(3):307-11 [PubMed] Related Publications
OBJECTIVE: To investigate the effect of interleukin-8 (IL-8) on the apoptosis of MCF-7 human breast cancer cells and the molecular mechanism.
METHODS: The expressions of IL-8 receptors (CXCR1, CXCR2) in MCF-7 cells were detected by Western blotting. The effects of 0, 20, 40, 80, 160 ng/mL IL-8 on the expressions of apoptosis-related genes Bcl-2 and caspase-3 in MCF-7 cells were observed by reverse transcription PCR(RT-PCR) and Western blotting. Cell proliferation was determined by CCK-8 assay after 0, 40, 80 ng/mL IL-8 treatment. Phase contrast microscope was used to examine cell morphology of MCF-7 cells after 80 ng/mL IL-8 treatment. The effects of 80 ng/mL IL-8 combined with PD980590 (10 μmol/L), LY294002 (10 μmol/L) or AG490 (50 μmol/L) [mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK), Janus kinase/signal transducer and activator of transcription (JAK/STAT) signal pathway inhibitors, respectively], on the expression of Bcl-2 were detected by Western blotting. The effects of 0, 20, 40, 80, 160 ng/mL IL-8 on the expression of p-AKT in MCF-7 cells were observed by Western blotting. The effects of 80 ng/mL IL-8 combined with 10 μmol/L LY294002 on the apoptosis of MCF-7 cells, the expressions of Bcl-2 and caspase-3 were determined by flow cytometry, RT-PCR and Western blotting, respectively.
RESULTS: Both CXCR1 and CXCR2 were expressed in MCF-7 cells. IL-8 markedly up-regulated the anti-apoptotic gene Bcl-2, down-regulated the pro-apoptotic gene caspase-3, and significantly inhibited the apoptosis of MCF-7 cells. However, these effects were blocked by phosphoinositide 3-kinase/protein kinase B (PI3K/AKT), signal pathway inhibitor LY294002. As predicted, IL-8 markedly increased the expression of p-AKT in MCF-7 cells.
CONCLUSION: IL-8 might significantly inhibit the apoptosis of MCF-7 cells. This effect may be achieved by up-regulating Bcl-2 and down-regulating caspase-3 via PI3K/AKT signal pathway.

Disclaimer: This site is for educational purposes only; it can not be used in diagnosis or treatment.

Cite this page: Cotterill SJ. Breast Cancer, Cancer Genetics Web: http://www.cancer-genetics.org/X0401.htm Accessed:

Creative Commons License
This page in Cancer Genetics Web by Simon Cotterill is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Note: content of abstracts copyright of respective publishers - seek permission where appropriate.

 [Home]    Page last revised: 08 August, 2015     Cancer Genetics Web, Established 1999